Investigation of Neuronal Manganese Regulation in Physiology and Disease Using High Throughput Screening, Induced Pluripotent Stem Cells, and Chemical Biology Approaches. by Kumar, Kevin Krishan
Investigation of neuronal manganese regulation in physiology and disease using high throughput screening, 
induced pluripotent stem cells, and chemical biology approaches 
 
By 
Kevin Krishan Kumar 
 
Dissertation 
Submitted to the Faculty of the 
Graduate School of Vanderbilt University 
in partial fulfillment of the requirements 
for the degree of 
DOCTOR OF PHILOSOPHY 
in 
Neuroscience 
December, 2014 
Nashville, Tennessee 
 
 
Approved: 
Kevin C. Ess, M.D., Ph.D. 
 
Michael Aschner, Ph.D. 
 
Joseph S. Neimat, M.D., M.S. 
 
Daniel O. Claassen, M.D., M.S. 
 
C. David Weaver, Ph.D. 
 
Aaron B. Bowman, Ph.D.
To my grandparents, parents, and family for their inspiration and support
	  	  iii 
ACKNOWLEDGEMENTS 
 
My progress throughout graduate school would not have been possible without the support of my mentors, 
colleagues, and friends. I especially wish to acknowledge my mentor Dr. Aaron Bowman for his training and 
guidance during this critical stage of my academic career. Dr. Bowman has constantly challenged me to 
innovate, overcome obstacles, and develop my analytical skills. In addition, Dr. Bowman has trained me in the 
art of scientific communication, encouraging me to write research grants, present my work at national meetings, 
and publish in peer-reviewed journals. 
 
I also would like to acknowledge my fellow laboratory members Dr. Asad Aboud, Dr. Diana Neely, Dr. 
Bingying Han, Michael Uhouse, Andrew Tidball, Terry Jo Bichell, Miles Bryan, Kyle Horning, and others over 
the years. I would also like to acknowledge our undergraduate students JohnJohn Sun, Mihir Odak, Idine 
Mousavi, and Emma Bradley. The collaborative environment, lively discussions, and camaraderie have made 
the past three years a pleasure. 
 
The rapid advances made on my project would not have been possible without the advice, guidance, and 
technical expertise of our collaborators: Dr. Michael Aschner (Albert Einstein College of Medicine), Dr. Kevin 
Ess, Dr. David Weaver, Dr. Jens Meiler, Dr. Paige Vinson, Dr. Rey Redha, Dr. Chris Farmer, Dr. Joshua Bauer, 
Dr. Cody Goodwin, and Dr. John McLean. I also wish to recognize members of my thesis committee, Dr. 
Joseph Neimat and Dr. Daniel Claassen, for their scientific and clinical mentorship. 
 
Furthermore, I wish to express my sincere gratitude to Dr. Terence Dermody, Dr. Larry Swift, Dr. Michelle 
Grundy, Dr. Jim Bills, Melissa Krasnove, and the rest of the Medical Scientist Training Program at Vanderbilt 
University for providing the unique opportunity to train as a physician-scientist. The program has been highly 
supportive of my training goals and has advised me on the nuances of balancing a clinical and research career.  
 
I am also thankful for the training and opportunities provided by the Vanderbilt Brain Institute and 
Neuroscience Graduate Program. In particular, Dr. Mark Wallace, Dr. Douglas McMahon, Rosalind Johnson, 
and Mary Michael-Woolman have been tremendously supportive and instrumental throughout graduate school. 
 
I also wish to acknowledge our sources of funding throughout the project: NIGMS T32 GM07347 to the 
Vanderbilt Medical Scientist Training Program, NIH P30 ES000267 (Bowman), R01 ES016931 (Bowman), 
R01 ES010563 (Bowman/Aschner). 
 
My entry into the physician-scientist pathway would not have been possible without my high school and 
undergraduate mentors: Dr. Mone Zaidi (Mount Sinai School of Medicine), Dr. Daniel Barbash (Cornell 
University), Dr. Joseph Safdieh (Weill Cornell Medical College), and Dr. Jay Gingrich (Columbia University). 
Their support and advice throughout my undergraduate studies at Cornell and graduate studies at Vanderbilt 
have been invaluable. 
 
Finally, I am immensely grateful for the unwavering support and sacrifice of my parents, grandparents, and 
family. Their tireless work ethic and standards of excellence continue to push me to take full advantage of the 
opportunities I have been given in life. I would also like to recognize Jyoti Duggal for her patience and 
encouragement throughout my academic journey. 
 
	  	  iv 
TABLE OF CONTENTS 
 
Page 
DEDICATION ........................................................................................................................................................ ii 
ACKNOWLEDGEMENTS ................................................................................................................................... iii 
LIST OF TABLES ................................................................................................................................................. vi 
LIST OF FIGURES ............................................................................................................................................... vii 
Chapter 
I. Manganese as a risk factor for neurodegenerative disease ............................................................................ 1 
Introduction .................................................................................................................................................... 1 
Physiological role of Mn in the nervous system ............................................................................................ 1 
Parkinsonism, Parkinson’s disease, and Huntington’s disease: links to Mn .................................................. 2 
II. Manganese transport in neurons ..................................................................................................................... 7 
Neuronal Mn transport: a black box of cell biology ...................................................................................... 7 
A novel approach to understanding neuronal Mn regulation ....................................................................... 11 
 
III. The potential of induced pluripotent stem cells as a translational model for neurotoxicological risk ......... 15 
Abstract ........................................................................................................................................................ 15 
Introduction .................................................................................................................................................. 16 
The promise of iPSC technology for neurotoxicology ................................................................................. 18 
Methods of hiPSC generation ...................................................................................................................... 21 
Special considerations and technical challenges for iPSC-based neurotoxicological applications ............. 22 
The potential hiPSC technology for personalized medicine and risk assessment ........................................ 40 
Conclusions .................................................................................................................................................. 42 
IV. Optimization of fluorescence assay of cellular manganese status for high throughput screening ............... 44 
Abstract ........................................................................................................................................................ 44 
Introduction .................................................................................................................................................. 45 
Results .......................................................................................................................................................... 47 
Discussion .................................................................................................................................................... 56 
Materials and Methods ................................................................................................................................. 59 
 
 
	  	  v 
V. Cellular manganese content is developmentally regulated in human dopaminergic neurons ...................... 62 
Abstract ........................................................................................................................................................ 62 
Introduction .................................................................................................................................................. 63 
Results .......................................................................................................................................................... 65 
Discussion .................................................................................................................................................... 86 
Materials and Methods ................................................................................................................................. 88 
VI. Untargeted metabolomics in Huntington’s disease striatal cell model shows disease-dependent and 
disease-manganese interactions in metabolic pathways ............................................................................... 92 
 
Abstract ........................................................................................................................................................ 92 
Introduction .................................................................................................................................................. 93 
Results .......................................................................................................................................................... 96 
Discussion .................................................................................................................................................... 98 
Conclusions ................................................................................................................................................ 102 
Materials and Methods ............................................................................................................................... 103 
VII. Regulation of neuronal Mn in physiology and disease: conclusions and future directions ....................... 109 
Regulation of Mn content in dopaminergic neurons .................................................................................. 109 
Efficacy of the small molecule toolbox ...................................................................................................... 110 
Future directions ......................................................................................................................................... 112 
A multidisciplinary approach to reveal new therapeutic targets for disease .............................................. 115 
 
REFERENCES .................................................................................................................................................... 117 
	  	  vi 
LIST OF TABLES 
 
Table Page 
1. Representative protocols for differentiation of hiPSC and hESC to region-specific neuroprogenitors .......... 27 
2. Representative protocols for differentiation of hiPSCs and hESCs to mature neurons .................................. 28 
3. Generation of glutamatergic and dopaminergic neurons by direct conversion from fibroblasts .................... 29 
4. Z-factors by batch and plate ............................................................................................................................ 55 
5. Chemical structures of all 41 validated small molecules in the Mn toolbox .................................................. 70 
6. Measured accurate masses for metabolite identifications ............................................................................... 97 
 
	  vii 
LIST OF FIGURES 
 
Figure Page 
1. Major neuronal Mn transporters ........................................................................................................................ 8 
2. Summary schematic of approach to studying neuronal Mn biology ............................................................... 13 
3. Generation of human induced pluripotent stem cells for neurotoxicological studies ..................................... 23 
4. Determination of optimal cellular density and exposure time of CFMEA ..................................................... 48 
5. Optimization of fura-2 concentration and extraction volume ......................................................................... 50 
6. 0.75µM fura-2 standard curve ......................................................................................................................... 51 
7. Sources of variability and analytical technique ............................................................................................... 54 
8. HTS identifies modulators of neuronal Mn status .......................................................................................... 66 
9. Checkerboard assay HTS-CFMEA pre- and post-assay optimization using Alexa-568 to control for 
variability in volumetric delivery .................................................................................................................... 67 
 
10. Concentration response curves (CRCs) of primary screen hits ....................................................................... 67 
11. Native fluorescence of validate small molecules at fura-2 excitation/emission wavelength .......................... 68 
12. Toxicity of small molecules in the Mn toolbox .............................................................................................. 69 
13. Structure activity dendrogram and Tanimoto plot of Mn toolbox .................................................................. 78 
14. Activity of validated small molecules at physiological and toxicological Mn exposures .............................. 80 
15. Chemical informatics analysis of Mn toolbox ................................................................................................ 82 
16. Mn accumulation changes across developmental time in mesencephalic floor-plate neuroprogenitors    
and/or post-mitotic dopaminergic neurons ...................................................................................................... 83 
 
17. Mn toolbox is effective in hiPSC-derived mesencephalic floor-plate neuroprogenitors and/or post-mitotic 
dopaminergic neurons ..................................................................................................................................... 85 
 
18. Study of HD-Mn interaction using untargeted metabolomics ........................................................................ 95 
19. Untargeted metabolomics reveals metabolites impacted by Mn and/or HD genotype ................................... 98 
20. Metabolic disruption in Huntington’s disease ............................................................................................... 102 
	  viii 
 
21. Intact and mobility-selected fragmentation spectra for glutathione. ............................................................. 106 
22. Fragmentation spectra for ribulose 5-phosphate ........................................................................................... 106 
23. Isotopic envelope suggesting ubiquitin identification ................................................................................... 107 
24. Pantothenic acid fragmentation spectrum ..................................................................................................... 107 
25. Mobility-selected high and low energy spectra for isobutyryl carnitine ....................................................... 108  
26. Competition experiments for GSK Published Kinase Inhibitor Set small molecules ................................... 114 
 
 
	  1 
CHAPTER I 
 
MANGANESE AS A RISK FACTOR FOR NEURODEGENERATIVE DISEASE 
 
Introduction 
 
Neurodegenerative diseases are expected to be the second most common cause of death among the elderly by 
2040 (Lilienfeld et al. 1993). Thus, it has become a priority to develop novel prevention strategies and 
treatments for these devastating illnesses. Despite identification of genetic and environmental factors that hasten 
degeneration, there is a dearth of information about the gene-environment interface that underlies selective 
neuronal vulnerability. One such environmental exposure, manganese (Mn), is neurotoxic and causes basal 
ganglia dysfunction and neurodegeneration. Specifically, Mn exposure is an environmental risk factor for 
parkinsonism and modulation of neuronal Mn status has been observed in the pathogenesis of Huntington’s 
disease (HD) (Gorell et al. 1999, Kim et al. 1999, Gorell et al. 2004, Bowman et al. 2011). Given the known 
links of alterations in Mn biology with neurodegenerative disease, manipulation of neuronal Mn represents an 
attractive protective and therapeutic target for these disorders. However, the processes regulating intracellular 
Mn are poorly understood, hampering efforts to pharmacologically modify neuronal Mn handling. 
 
Physiological role of Mn in the nervous system 
 
Mn is required for several physiological processes vital for the nervous system function. These processes 
include its role as a co-factor for several metalloenzymes, including arginase, glutamine synthetase, 
phosphoenolpyruvate decarboxylase, serine threonine carboxylase, and Mn-superoxide dismutase (Mn-SOD) 
(Takeda 2003, Aschner et al. 2005). Maintenance of Mn levels in the nervous system is essential, as deviation 
from normal levels can cause neuronal dysfunction. Although tissue levels of Mn are highly regulated, acute 
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and chronic exposures can lead to CNS accumulation. For example, increased Mn levels are known to disrupt 
the levels of γ-aminobutyric acid (GABA), dopamine, and glutamate in the brain (Seth et al. 1984, Aschner et 
al. 2002, Takeda 2003). Mn preferentially accumulates in the substantia nigra pars compacta (SNpc), globus 
pallidus, and striatum; areas highly sensitive to oxidative injury and stress (Newland et al. 1989, Olanow 2004, 
Cersosimo et al. 2006, Guilarte 2010). Intracellular localized Mn predominantly accumulates in the 
mitochondria, where it interferes with cellular respiration and increases reactive oxygen species (ROS) 
production via inhibition of mitochondrial respiratory Complex I (Aschner et al. 2005, Bowman et al. 2011). 
 
Parkinsonism, Parkinson’s disease, and Huntington’s disease: links to Mn 
 
Parkinsonism and Parkinson’s disease 
 
Parkinson’s disease (PD) is the second most common neurodegenerative disease. The prevalence of PD in the 
industrialized world is estimated at 0.3% of the general population and approximately 1% in individuals over 
the age of 60 (Nussbaum et al. 2003). Thus, PD is considered an age-related disease, with prevalence rising 
mainly after the age of 50 (Li et al. 1985, Schoenberg et al. 1988, Morgante et al. 1992, Tison et al. 1994, de 
Rijk et al. 1995, Mayeux et al. 1995, Fall et al. 1996, de Rijk et al. 1997, Claveria et al. 2002, Benito-Leon et 
al. 2003, de Lau et al. 2006). As the population ages, there is an increasing socioeconomic burden on society 
(de Lau et al. 2006). The incidence of PD is 8 to 18 per 100,000 person-years (de Rijk et al. 1995, de Lau et al. 
2006). It has been noted that there is higher prevalence of PD in men than women, a finding hypothesized to be 
mediated by a neuroprotective role of estrogens (Morgante et al. 1992, Tison et al. 1994, de Rijk et al. 1995, de 
Rijk et al. 1997, de Lau et al. 2006). 
 
PD diagnosis is contingent on presentation with at least two of the four cardinal symptoms of parkinsonism: 
resting tremor, bradykinesia, rigidity, and postural instability (de Lau et al. 2006). This clinical suspicion is 
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further supported by the patients’ responsiveness to levodopa, asymmetry of symptoms, or SPECT imaging 
with DaTSCAN, although the latter is seldom used as a primary diagnostic procedure (Litvan et al. 2003, 
Tolosa et al. 2007). Furthermore, secondary causes of parkinsonism such as drug-induced parkinsonism must be 
excluded to achieve a diagnosis of PD. Interestingly, the course of PD is highly variable; studies analyzing PD 
progression suggest that functional deterioration is accelerated both early in the disease course and among 
patients presenting with postural instability gait difficulty (Jankovic et al. 2001, Lang 2007, Post et al. 2007, 
Jankovic 2008). 
 
The majority (90%) of PD cases are sporadic in etiology with the remaining 10% of cases having known genetic 
causes. Furthermore, there is profound heterogeneity in age of onset, neuropathological findings, and 
characteristic symptoms even among the genetic forms of PD. Mn exposure is a major environmental risk factor 
for PD (Hudnell 1999). A national study revealed in urban areas incidence of PD is greater where emissions of 
Mn are highest (Weisskopf et al. 2010, Willis et al. 2012). Furthermore, long-term residence in areas with high 
cumulative industrial Mn release is associated with an increased PD incidence and risk (Willis et al. 2010). In 
particular, inhalational exposure has been well studied in welding, smelting, and mining (Schuler et al. 1957, 
Wang et al. 1989, Racette et al. 2001).  In addition, excess Mn intake through drinking water and dietary 
sources has been associated with other neuropathologies suggesting potential application to parkinsonism and 
PD (Iwami et al. 1994, Iwami et al. 1994). Developmental exposure to Mn is also a concern because the organic 
compound methylcyclopentadienyl manganese tricarbonyl (MMT) is used as an anti-knock agent in petrol. 
Non-occupational exposures have had noted associations with Parkinsonian disorders in communities located in 
the vicinity of ferroalloy industries (Lucchini et al. 2007). 
 
Notably, PD is distinct from the extrapyramidal motor syndrome manganism, which has similar clinical features 
including rigidity, bradykinesia, tremor, and dystonic movements (Newland et al. 1989, Calne et al. 1994, 
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Olanow 2004, Samii et al. 2004, Cersosimo et al. 2006, Guilarte 2010). PD differs profoundly from manganism 
in etiology; the latter is exclusively caused by excessive Mn deposition in the brain.  
 
Although a complete understanding of the pathogenesis of PD remains elusive, current evidence suggests that 
PD results from a multitude of factors including: oxidative stress, protein aggregation, and mitochondrial 
dysfunction (Greenamyre et al. 2004). In addition, the study of the genetic forms of PD has offered insight 
regarding central mechanisms in PD pathogenesis. Defective proteins in familial PD result from mutations in 
genes that function in critical cellular processes such as the ubiquitin proteasome system (UPS), vesicle 
trafficking, mitochondrial function, and oxidative stress responses (Jakes et al. 1994, Mori et al. 2002, 
Nuytemans et al. 2010). 
 
On a cellular level, PD is characterized by loss of dopaminergic neurons of the substantia nigra and the presence 
of intraneuronal protein aggregates composed of α-synuclein known as Lewy bodies (Wood-Kaczmar et al. 
2006). Loss of dopamine levels in the striatum leads to downstream dysregulation of basal ganglia motor 
circuitry resulting in the motor symptoms observed in PD. While there is a common endpoint of decreased 
striatal dopamine levels, multiple pathways can influence an individual’s pattern of neuronal cell death and the 
mechanism by which it occurs.  For example, dysfunction in mitochondrial complex I results in upregulated free 
radical production causing protein damage. The damaged protein burden increases the stress on the UPS, 
leading to protein aggregation and subsequent neuronal death (Ali et al. 2011). However, this simple pathway 
could be influenced at any level by multiple inputs such as environmental toxins, genetic risk, and enhanced 
oxidative stress. Thus, an individual patient’s history of environmental exposure and genetic risk are critical to 
their clinical manifestation of PD. 
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Huntington’s Disease 
 
HD is an autosomal dominant, neurodegenerative disorder characterized by chorea, dystonia, cognitive decline, 
and behavioral abnormalities (Walker 2007). HD is caused by a CAG repeat expansion (with repeats of ~36 and 
higher being pathogenic) within the widely expressed Huntingtin (HTT) gene (Rubinsztein et al. 1996, McNeil 
et al. 1997, Rubinsztein et al. 2003, Walker 2007). HTT is expressed in all mammalian cells with highest 
concentrations in the brain and testes, followed by liver, heart, and lungs (DiFiglia et al. 1995). CAG repeat 
length in HTT is inversely correlated with time to diagnosis for HD, accounting for 44% of variation in age of 
onset (Brinkman et al. 1997, Wexler et al. 2004). Despite its wide expression pattern, the function of HTT and 
its role in HD pathogenesis is poorly understood. 
 
HD has an overall prevalence of 0.38 per 100,000 per year (Pringsheim et al. 2012). The incidence varies by 
ethnicity, with 5-7 per 100,000 individuals in the white population and 0.5 per 10,000 in the Japanese 
population (Pridmore 1990, Takano et al. 1998, Walker 2007). Notably, HD has a lower incidence in other 
Asian and African populations (Hayden 1981, Wright et al. 1981, Bates et al. 2002). The prevalence of HD 
varies to 5.70 per 100,000 in Europe, North America, and Australia compared to 0.40 per 100,000 in Asia. The 
disparity in HD prevalence is attributed to difference in HTT gene haplotypes (Pringsheim et al. 2012). 
 
HD diagnosis can be achieved anytime between the ages of 1 and 80 years of age, composed of a healthy period 
followed by a prediagnostic phase and final diagnostic phase. The prediagnostic phase is characterized by subtle 
change in motor control, cognition, and personality (Snowden et al. 1998, Walker 2007).  Symptoms worsen 
until chorea, incoordination, motor impairment, and disruptions of saccadic eye movements are reported 
(Walker 2007). 
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Exhibiting some overlap with PD-neuroanatomical localization, typical adult-onset HD is characterized by 
degeneration of neurons within the corpus striatum, cortex, and hypothalamus (Cowan et al. 2006, Hult et al. 
2010). Striatal medium spiny neurons (MSNs) are the most vulnerable cell type. Specifically, those neurons 
containing substance P and project to internal globus pallidus are more involved with disease pathology, while 
interneurons are generally spared (Walker 2007). The preferential dysfunction of thalamocortical circuitry 
generates chorea early in the course of HD given the involvement of the indirect pathway (Paulsen et al. 2005). 
There is also notable cell loss in the cortex, hippocampus, and parietal lobe, lateral tuberal nuclei of the 
hypothalamus, centromedial-parafasicular complex of the thalamus and Purkinje cells of the cerebellum (Jeste 
et al. 1984, Kremer et al. 1991, Kremer 1992, Spargo et al. 1993, Macdonald et al. 1997, Macdonald et al. 
2002).  These cells contain nuclear and cytoplasmic inclusions containing mutant huntingtin and polyglutamine 
(Davies et al. 1997). It is still unclear what role these inclusions play in HD pathogenesis, as they appear before 
symptom onset and fail to predict cellular dysfunction or disease activity (Gomez-Tortosa et al. 2001, Arrasate 
et al. 2004, Kaytor et al. 2004, Mukai et al. 2005, Van Raamsdonk et al. 2005). 
 
Given the aforementioned finding that CAG repeat length accounts for less than half of variation in age of 
onset, there has been considerable interest in the role of environmental factors in modulation of disease 
progression in HD (Georgiou et al. 1999, Wexler et al. 2004, Friedman et al. 2005, van Dellen et al. 2005, 
Gomez-Esteban et al. 2007). In regards to Mn, changes in Mn dependent enzymatic activity have been observed 
that postmortem brains of HD patients (Butterworth 1986). Furthermore, expression of mutant HTT has been 
associated with decreased striatal Mn levels and alterations in the metabolism, transport, and/or toxicity of Mn 
(Williams et al. 2010, Williams et al. 2010). The lack of knowledge regarding the functional role of HTT has 
further complicated studies, since there are limited known targets and interacting proteins.
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CHAPTER II 
 
MANGANESE TRANSPORT IN NEURONS 
 
Neuronal Mn transport: a black box of cell biology 
 
Mn transport has been well described at the systemic level, including regulatory processes in the gut, blood 
brain barrier, and glia. For example, Mn is known to enter across cerebral capillaries at the blood brain barrier 
where it crosses the chorioid plexus in the cerebrospinal fluid (Aschner et al. 2005, Yokel 2009, Tuschl et al. 
2013). However, the transport of Mn at the neuronal level remains poorly understood. The best-described 
processes for regulating neuronal Mn are those shared transporters used by other divalent metals such as iron 
(Fe) and calcium (Ca). These transporters include voltage regulated and ionotropic glutamate receptor Ca2+ 
channels, transient receptor potential cation channel, subfamily M, member 7 (TRPM7), store operated Ca2+ 
channel, and transferrin (Tf)-dependent and independent process via divalent metal transporter 1 (DMT1), and 
solute carrier (SLC) channels (including ZIP proteins) (Figure 1) (Kannurpatti et al. 2000, Riccio et al. 2002, 
Grimm et al. 2003, Roth et al. 2003, Aschner et al. 2006, Erikson et al. 2006, Garrick et al. 2006, He et al. 
2006, Dean et al. 2009, Himeno et al. 2009, Yokel 2009, Fujishiro et al. 2011, Roth et al. 2013). These 
transport systems appear to only account for a proportion of total Mn, and are thought to be inadequate to 
handle acute and chronic exposures of Mn. 
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Figure 1 – Major neuronal Mn transporters. Representative Mn import (green) and efflux (red) transporters 
transport Mn along with other cations. Divalent metal transporter 1 (DMT1), ferroportin (Fpn), voltage 
regulated Ca2+ channel (VRCC), transient receptor potential cation channel, subfamily M, member 7 (TRPM7), 
solute carrier family 30, member 10 (SLC30A10), ionotropic glutamate receptor channel (NMDA), transferrin 
receptor (TfR) and ZIP8/14 (ZIP). Mn oxidation state is indicated as either Mn2+ or Mn3+, which can be bound 
to transferrin (Tf). 
 
 
Among these known transporters, DMT1 is one of the best studied, exhibiting specificity for a variety of 
divalent cations included Fe2+, Mn2+, Cd2+, Ni2+, Co2+, and Pb2+ (Gunshin et al. 1997, Mackenzie et al. 2007). 
DMT1 primarily functions as a Fe transporter, but exhibits similar affinity for Mn. Both Mn and Fe can be 
transported by both Tf-independent and dependent routes, processes well described in metal transport from the 
apical surface of intestinal enterocytes. It is unclear what role DMT1 plays in neuronal Mn transport, but the 
highest expression levels of DMT1 are found in the dopaminergic areas of the basal ganglia, areas of noted Mn 
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toxicity (Huang et al. 2004).  One of the few areas of demonstrated DMT1-mediated transport on the neuronal 
level is in the presynaptic endings of olfactory bulb (Thompson et al. 2007). However, it is unknown if neurons 
in other regions of the brain utilize a similar transport mechanism, representing a major gap in the knowledge of 
neuronal Mn regulation. In addition, DMT1-mediated processes are likely not Mn-dependent, as expression of 
DMT1 isoforms is regulated by iron response elements (IREs), allowing Mn content to change based on in vivo 
Fe levels (Garcia et al. 2007, Fitsanakis et al. 2008, Hansen et al. 2009, Nunez et al. 2010). Consequently, 
DMT1-mediated transport has potential to contribute to disruption of Mn homeostasis in pathologies where Fe 
levels are impacted, such as hemochromatosis or anemia. 
 
Alternatively, Tf-dependent transport mechanisms are known to traffic Mn when in its trivalent state Mn3+. The 
trivalent state, normally found in the blood, permits access to binding sites on Tf. This Mn3+-Tf complex is 
highly stable, and is slowly cleared by the hepatobiliary system (Roth et al. 2013). However compared to Mn, 
Tf has higher affinity for Fe and can carry other metals making it subject to disruptions in Fe levels. 
Furthermore, due to its pH and oxygen content, it is hypothesized that limited Mn3+ exists in the brain, limiting 
the ability of Tf-mediated routes to function as a major mechanism of neuronal Mn regulation (Roth et al. 
2013). In addition, there exist alternate routes for non-protein-bound forms of Mn to cross the blood brain 
barrier, such as Mn citrate, but their role at the level of neurons is unknown (Crossgrove et al. 2003). 
 
Another route of Mn transport is through the ZIP-family metal transporters. These proteins function as divalent 
cation/HCO3- symporters (He et al. 2006, Liuzzi et al. 2006, Girijashanker et al. 2008, Fujishiro et al. 2011). 
Two of the most well-studied ZIP proteins, ZIP8 and ZIP14, have a high degree of homology and share the 
ability to transport divalent metals including Mn2+ (Pinilla-Tenas et al. 2011).  Unlike Tf-mediated transport, 
ZIP-mediated transport has the potential to transport a considerable proportion of Mn2+, the predominant 
oxidation state found in the brain. However, this potential role in neurons is dubious given that ZIP-mediated 
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transport has only been established in the blood brain barrier, proximal convoluted tubule of the kidney, and in 
the liver (Girijashanker et al. 2008, Himeno et al. 2009, Fujishiro et al. 2012). 
 
Similar to other routes, Mn can also be transported through Ca2+ channel-dependent transporters. There are 
several known types of transporters including voltage regulated, ionotropic glutamate receptor Ca2+ channels, 
TRPM7, and store operated Ca2+ channels (Lucaciu et al. 1997, Kannurpatti et al. 2000, Loutzenhiser et al. 
2000, Riccio et al. 2002, Grimm et al. 2003, Yokel et al. 2004, Yokel 2009, Roth et al. 2013). Blockage of the 
voltage regulated Ca2+ channels, eliminates depolarization induced Mn uptake into cells (Lucaciu et al. 1997, 
Loutzenhiser et al. 2000). Similarly, inhibition of the ionotropic glutamate receptor Ca2+ channel has been 
shown to attenuate Mn induced toxicity while inhibitors of the sarcoplasmic reticulum Ca-ATPase induces Mn 
uptake (Jardin et al. 2009). It has also been demonstrated that modulation of expression of TRPM7 has been 
shown to change cellular Mn levels (Guilbert et al. 2009). Although each of these aforementioned 
characteristics of Ca2+ channel-dependent transporters has been studied in a diverse range of cell types found in 
the blood, kidney, and breast, the specific role of these transporters in neurons is undefined. 
 
Notably, while there are several well-studied Mn transport routes that modulate uptake, modulators of Mn 
efflux could play a significant role in neuronal Mn homeostasis. One of these efflux mechanisms, Fpn, is widely 
expressed in all cell types including neurons (Moos et al. 2006). Induction of Fpn expression reduced Mn-
induced toxicity and cellular Mn content (Yin et al. 2010). However, Fpn-mediated efflux is not Mn specific 
and is known to transport other divalent metals including Fe. Other routes of Mn efflux have pathological 
significance. Disruptions of neuronal Mn efflux have been reported in case of patients with Mn transporter 
deficiency due to mutations in SLC30A10 (Gospe et al. 2000, Quadri et al. 2012, Stamelou et al. 2012, Tuschl 
et al. 2012, Lechpammer et al. 2014). Neuropathological findings in a patient with homozygous mutations in 
SLC30A10 include neuronal loss, astrocytosis, myelin loss, and spongiosis in the basal ganglia (Lechpammer et 
al. 2014). In addition, depigmentation of the substantia nigra and a 16-fold increase in Mn content within the 
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basal ganglia was observed (Lechpammer et al. 2014). These patients also exhibited hepatic dysfunction, 
suggesting that SLC30A10 mediated transport is not neural specific, and its contribution relative to all routes of 
neuronal Mn homeostasis remains unknown. 
 
In addition to transporters that exchange Mn between the extracellular milieu and the cytosol, Mn can also be 
regulated at the intracellular level. For example, SPCA1 and SPCA2, Ca2+/Mn2+ ATPases, transport Mn2+ from 
the cytosol to the Golgi (Mukhopadhyay et al. 2011). These transporters are widely expressed and promote cell 
viability. The role of these transporters in neuronal Mn biology may have importance given that high Mn 
exposure mice accumulate Mn in brain regions with high SPCA1 expression (Sepulveda et al. 2007). Despite 
their therapeutic potential, the role of these intracellular regulators in neuronal Mn physiology remains a 
relatively unexplored scientific frontier. 
 
A novel approach to understanding neuronal Mn regulation 
 
Considered together, the known routes of cellular transport of Mn are neither metal nor neuronal-specific. 
Furthermore, there exists profound heterogeneity in the Mn concentrations in which the known transporters 
have been characterized, which include concentrations in excess of in vivo physiological relevance. The 
variation in the cell type and Mn exposure paradigm has made the development of a coherent model of neuronal 
Mn regulation difficult. The development of such a model is valuable given the critical role of Mn in neural 
development and function. We hypothesized that Mn-specific regulatory mechanisms exist in neurons, and 
perhaps other cells. These regulatory mechanisms should be pharmacologically targetable, allowing modulation 
of neuronal Mn content using small molecules. Thus, we developed an innovative approach using high 
throughput screening technology, permitting the interrogation of non-defined Mn homeostatic mechanisms to 
influence neuronal Mn biology.  
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In addition, we sought to explore Mn regulation in differentiating neurons given known Mn-related dysfunction 
in the developing brain. Blood Mn levels in schoolchildren have been significantly associated with 
environmental Mn levels (Rollin et al. 2005). Non-occupational childhood exposures are especially concerning, 
since they have been associated with lower cognitive performance (Wasserman et al. 2006, Bouchard et al. 
2011, Menezes-Filho et al. 2011). Early Mn exposure in neonates, measured by cord blood Mn concentrations, 
were associated with impaired neurobehavioral development (Takser et al. 2003). The ability of early childhood 
exposure to Mn to lead to neurological impairment suggests a plausible mechanistic requirement for developing 
neurons to carefully regulate Mn.  
 
We also sought to gain insight into the mechanisms through which modulation of an environmental stressor, 
such as Mn, alters neuronal function in the context of genotypic stressor, such as mutant HTT. The exploration 
of reduced Mn levels in striatal cells with mutant HTT has been difficult to study given the lack of knowledge 
regarding mechanisms linking HD and Mn at the neuronal level. Thus, we sought to employ an untargeted 
metabolomics to discover any Mn-specific, genotype-specific, and/or Mn-genotype changes in cellular 
metabolites in murine striatal cells.  
 
This multidisciplinary approach allowed us to investigate the processes underlying Mn regulation and their 
implications for neurodegenerative pathologies (Figure 2). 
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Figure 2 – Summary schematic of approach to studying neuronal Mn biology. The use of high throughput 
screening, induced pluripotent stem cell (iPSC) technology, and untargeted metabolomics can lend insight into 
the processes underlying neuronal Mn handling. Figure adapted from (Bleicher et al. 2003, Domaille et al. 
2008, Vinayavekhin et al. 2010) and <http://www.nobelprize.org/nobel_prizes/medicine/laureates/2012/ 
med_image_press_eng.pdf>. 
 
 
In subsequent chapters, the findings from three major studies: (1) a high throughput screen for novel modulators 
of Mn content, (2) examination of regulation of cellular Mn content in human mesencephalic dopaminergic 
neural precursors, (3) untargeted metabolomics study of HD-Mn interactions will be discussed. The technical 
foundation of these studies will first be established, consisting of a comprehensive review of neurotoxicological 
applications of induced pluripotent stem cell technology (Chapter III) and optimization of the Cellular Fura2 
Mn Extraction Assay (CFMEA) for HTS (Chapter IV). The results of the high throughput screen and 
application to human dopaminergic neurons will then be discussed (Chapter V) followed by the findings of the 
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untargeted metabolomic study of HD-Mn interactions in striatal cells (Chapter 6). The final portion of the 
dissertation, Chapter VII, is comprised of a discussion and summary of the findings and their translational 
applications for neurodegenerative disease.
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CHAPTER III 
 
THE POTENTIAL OF INDUCED PLURIPOTENT STEM CELLS AS A TRANSLATIONAL MODEL 
FOR NEUROTOXICOLOGICAL RISK1 
 
Abstract 
 
An important goal of neurotoxicological research is to provide relevant and accurate risk assessment of 
environmental and pharmacological agents for populations and individuals. Owing to the challenges of human 
subject research and the real possibility of species specific toxicological responses, neuronal lineages derived 
from human embryonic stem cells (hESCs) and human neuronal precursors have been offered as a potential 
solution for validation of neurotoxicological data from model organism systems in humans. More recently, with 
the advent of induced pluripotent stem cell (iPSC) technology, there is now the possibility of personalized 
toxicological risk assessment, the ability to predict individual susceptibility to specific environmental agents, by 
this approach. This critical advance is widely expected to facilitate analysis of cellular physiological pathways 
in the context of human neurons and the underlying genetic factors that lead to disease. Thus this technology 
opens the opportunity, for the first time, to characterize the physiological, toxicological, pharmacological and 
molecular properties of living human neurons with identical genetic determinants as human patients. 
Furthermore, armed with a complete clinical history of the patients, human iPSC (hiPSC) studies can 
theoretically compare patients and at risk groups with distinct sensitivities to particular environmental agents, 
divergent clinical outcomes, differing co-morbidities, and so forth. Thus iPSCs and neuronal lineages derived 
from them may reflect the unique genetic blueprint of the individuals from which they are generated. Indeed, 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1 Reprinted from Neurotoxicology, 33, Kevin K. Kumar, Asad A. Aboud, Aaron B. Bowman, Induced 
Pluripotent Stem Cells As A Future Translational Model For Neurotoxicological Risk, 518-29, Copyright 
(2012), with permission from Elsevier. 
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iPSC technology has the potential to revolutionize scientific approaches to human health. However, before this 
overarching goal can be reached a number of technical and theoretical challenges must be overcome. This 
review seeks to provide a realistic assessment of hiPSC technology and its application to risk assessment and 
mechanistic studies in the area of neurotoxicology. We seek to identify, prioritize, and detail the primary 
hurdles that need to be overcome if personalized toxicological risk assessment using patient-derived iPSCs is to 
succeed. 
 
Introduction 
 
The field of toxicology has seen rapid innovation in the past two decades by the advent of stem cell technology.  
Perhaps the first major successful use of stem cells for the study of toxicity was the Embryonic Stem Cell Test 
(EST) developed by Speilmann and colleagues (Heuer et al. 1993, Spielmann et al. 1997). This approach 
differentiates mouse embryonic stem cells (ESCs) into cardiomyocytes in the presence of potential 
developmentally toxic agents (Heuer et al. 1993, Seiler et al. 2011). Although this method utilizes mouse stem 
cells, and focuses on differentiation into beating cardiomyocytes, the method has been broadly hailed for its 
ingenuity (Scholz et al. 1999, Laustriat et al. 2010, Wobus et al. 2011). However, the method has notable 
shortcomings in its application to neurotoxicology. For example, although the EST correctly classified the 
majority of known embryotoxic chemicals tested, it is known that the EST in some cases failed to correctly 
classify methylmercury as a developmental toxicant (Genschow et al. 2004). There are several potential reasons 
for these shortcomings of the EST – including species-specific toxicities and tissue-type specific toxicities. 
Recently, Bremer et al. sought to address both of these issues by adapting the principles of the EST to toxicity 
testing in human ESCs (hESCs) undergoing neuronal differentiation (Stummann et al. 2009). Their study 
showed greater sensitivity of early-developing neural precursors over maturing neuronal cells to methylmercury 
toxicity (i.e. greater changes in expression of key early neurodevelopmental markers versus more mature 
neuronal markers) (Stummann et al. 2009). Other groups have also provided proof-of-principle experiments 
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demonstrating the potential of hESCs to evaluate developmental toxicity (Pal et al. 2011). However, ethical and 
regulatory concerns about the use of cells derived from human embryos have limited adoption of hESC based 
toxicity testing (Leist et al. 2008, Vojnits et al. 2010).  
 
Pioneering studies have revealed both the feasibility as well as clear advantages for use of stem cell based 
approaches for neurotoxicological risk assessment. Although the fundamentals of stem cell culture are outside 
the scope of this review, a number of book chapters and review articles are available on this topic (Takahashi et 
al. 2007, Park et al. 2008, Neely et al. 2011).Studies using murine stem cells have identified mRNA based 
expression markers for assessment of neurodevelopmental toxicity (Kuegler et al. 2010, Theunissen et al. 
2011). Comparative studies using hESC derived neurons versus rodent primary neuronal cultures have revealed 
important differences in sensitivity, reproducibility, and dynamic ranges by toxicity measures examining neurite 
outgrowth and cytotoxicity; suggesting further work is needed in developing and interpreting hESC-derived 
neurotoxicity tests (Harrill et al. 2011). Indeed, toxicogenomic approaches revealed key differences on the 
influence of a developmental neurotoxicant on expression profiles between in vivo models, stem-cell based in 
vitro models and primary tissue/cell culture based models – yet also identified examples of coherent responses 
from the in vitro ESC-based models and in vivo measures (Robinson et al. 2011). Furthermore, predictive 
neurotoxicity testing by hESC-based neuronal differentiation approaches has proven successful in 
discriminating chemicals and pharmaceuticals with known developmental neurotoxicity (Buzanska et al. 2009). 
A related approach to hESC-based neurotoxicology has been to start developmentally down-stream of the 
pluripotent state and utilize multipotent human neuroprogenitors as a starting point for developmental 
neurotoxicity testing (Breier et al. 2008, Moors et al. 2009, Harrill et al. 2010, Schreiber et al. 2010, Harrill et 
al. 2011, Tofighi et al. 2011, Tofighi et al. 2011). Neuralization of pluripotent stem cells or neuroprogenitors 
can be accomplished either by adherent culture-based neuronal differentiation or a neurosphere suspension 
culture, which may be followed by subsequent plating, differentiation and migration. A discussion of the 
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advantages and disadvantages of these two approaches has been recently reviewed by Breier and colleagues 
(Breier et al. 2010).  
 
In this review, we seek to describe the methods of generating hiPSCs, explore the utility of this technology in 
the field of neurotoxicology, and discuss technical challenges for these applications. In addition, we will outline 
the process of generating and maintaining hiPSCs for toxicity testing, characterize multiple exposure 
paradigms, and attempt to predict the future of the field.  
 
The promise of iPSC technology for neurotoxicology 
 
A number of recent reviews have described potential applications of hESC and hiPSC technology to toxicology, 
pharmacology and the study of human diseases that have environmental contributions to their etiology (Heng et 
al. 2009, Saha et al. 2009, Winkler et al. 2009, Vojnits et al. 2010, Anson et al. 2011, Marchetto et al. 2011, 
Wobus et al. 2011). Here we focus on the promise and roadblocks specifically for neurotoxicological 
applications. An important advantage of a patient-specific iPSC approach to neurotoxicology is that 
environmental risk for an individual may be evaluated without a priori knowledge of the genetic risk factors. A 
complex relationship of environmental and genetic risk factors underlies many neurodevelopmental and 
neurodegenerative diseases – yet identification of causative factors has been severely hampered by the lack of 
suitable experimental models to account for the combinatorial influence of diverse toxicants and the inherent 
variation in human susceptibility and exposure. This complexity and variation of genetic and environmental 
influences between individuals also complicate epidemiological studies to identify contributors. For example, a 
link between pesticide exposure and Parkinson’s disease (PD) became suspected in 1983 with the discovery that 
exposure to 1-methyl 4-phenyl 1,2,3,6-tetrahydropyridine (MPTP), a compound with structural similarity to the 
pesticide paraquat, causes a selective degeneration of dopaminergic neurons in the substantia nigra (Langston et 
al. 1983, Elbaz et al. 2008). Despite epidemiological evidence potentially linking pesticide use with risk for PD, 
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discerning the role of specific pesticides in human disease has been difficult (Frigerio et al. 2006, Dick et al. 
2007, Dick et al. 2007, Kamel et al. 2007, Frigerio et al. 2009). Likewise, studies have found links between PD 
and exposure to Mn, Pb and other metals (Coon et al. 2006, Finkelstein et al. 2007). Interestingly, a recent 
study of a Chinese cohort found an association between blood Mn levels and PD, yet no differences in exposure 
were seen between control and disease groups (Fukushima et al. 2009). This raises the possibility that genetic 
risk factors may predispose some people to accumulate levels of this environmental toxicant thereby selectively 
increasing their risk for disease. The advent of hiPSC technology may provide researchers a method to test this 
and similar hypotheses, by allowing the evaluation of selective sensitivity to neurotoxicants across individual 
patients. 
 
The utility of human pluripotent stem cell technology towards human toxicological risk assessment rests on the 
idea that cells differentiated from patient-derived stem cells can serve as a model system for understanding the 
role of human genetic factors in modulating the vulnerability of differentiated cells to specific toxicants. A 
number of technical as well as theoretical hurdles need to be overcome before the utility of this approach can be 
realized. For example, efficiency and consistency of stem cell derivation, contribution of epigenetic changes, 
protocols for differentiation, exposure paradigms, and assessment of toxicity need to be optimized. Perhaps, 
though, the most fundamental issue that must be addressed upfront is whether the methods for generating 
patient-derived pluripotent stem cells are capable of yielding a consistent model of sensitivity to environmental 
toxicants. Direct tests are needed for the hypothesis that iPSCs derived from distinct individuals can be 
differentiated into neurons that exhibit toxicological sensitivity profiles specific to the subject from which they 
are derived. In other words, it needs to be shown that neuronal cells from multiple iPSC lines made from the 
same patient show more similarity in their sensitivity to specific neurotoxicants than neuronal cells from hiPSC 
lines of different patients. This simple question is fundamental for the development of an iPSC-based 
personalized toxicological risk assessment. 
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Additional technical considerations for early experimental applications of iPSC technology to 
neurotoxicological research are necessary. These include the importance of studying cell autonomous 
mechanisms of neurotoxicity. Owing to challenges in differentiation of specific neuronal populations and the 
consequential challenge in developing models of human neuronal circuits, it is likely unfeasible to explore 
neuronal network based toxicity until a better understanding of cell-autonomous toxicity is examined. For 
example, direct toxicity due to impaired mitochondrial function or effects of toxicants on specific cell signaling 
cascades need to be examined before realization of the down-stream consequences to neuronal network activity 
or intercellular signaling can be understood. Prototypical bench assays of toxicological measures need to be 
developed before automation or high-throughput screening of toxicants can be performed. Detailed examination 
of differentiation methods and the developmental trajectories and marker expression, as well as method-based 
influences on neurological phenotypes, need to be established before the impact of neurotoxicants on 
differentiation and neuronal activity can be interpreted in the context of predicting human neurodevelopmental 
toxicity. Indeed, validation of toxicological outcomes in iPSC-based models might best begin with human 
subjects (individuals with known genetic risk factors) and toxicants for which clearly understood human gene-
environment interactions exist to facilitate confidence in interpreting data for situations where risk factors are 
unknown. 
 
The study of the interactions between neurotoxicants and neurological disorders is an especially exciting future 
application of hiPSC technology, given the complexities of the diverse and ill-defined environmental and 
genetic risk factors. Furthermore, the ability to differentiate neurons and glia from patient hiPSCs offers the 
potential to examine changes in both the development and maintenance of neural function resulting from 
complex genetic inheritance patterns and toxicant perturbation (Liu et al. 2011). The ability to expand, 
maintain, culture, and differentiate hiPSCs may enable utilization of this resource by a broad range of 
laboratories throughout the US, and around the world, expanding both the scope and depth of research into 
human disease.  
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Methods of hiPSC generation 
 
In 2007 Yamanaka showed for the first time the possibility of transforming adult human fibroblasts to 
pluripotent stem cells using four defined transcription factors (Takahashi et al. 2007). This ground breaking 
discovery led the way to ample research in an attempt to both understand the molecular basis of stem cell 
induction and possible ways to improve it. Induced pluripotent stem cells (iPSCs) exhibit the typical 
characteristics of the inner mass-derived human embryonic stem cells, including self-renewal and the potential 
to differentiate to cell types of any of the three germ layers. In the original work by Yamanaka, after screening 
for 24 potential genetic targets, a set of four retrovirus-carried genes, namely OCT4, SOX2, c-MYC, and KLF4, 
were chosen to transduce human adult dermal fibroblasts. Further study of these factors revealed that except for 
OCT4, the requirement for these factors is not stringent. c-MYC, for example, was shown to be dispensable 
mainly for safety purposes, with a modest decrease in efficiency (Nakagawa et al. 2008). Similarly, c-MYC and 
KLF-4 could be replaced with NANOG and LIN28 with no significant effect on the outcome of stem cell 
induction (Yu et al. 2007).  
 
Because of serious drawbacks associated with the use of retroviruses for transduction, including persistent 
expression and insertional mutagenesis, alternative methods have been developed to deliver genes into the 
target cells. One of the strategies employs a doxycyclin inducible expression of the transgenes (Brambrink et al. 
2008). This diminishes the likelihood of constitutive transgene activation and could serve as an indicator of 
pluripotency since fully reprogrammed cells are not dependent on the exogenous factors for their self-renewal. 
Another way to control viral gene expression utilizes genes flanked by loxP sites, which could later be excised 
by transiently expressing Cre recombinase. Alternatively, PiggyBac transposons, mobile genetic elements that 
could be inserted into the genome, could be used instead of the transgenes. This is an attractive method as they 
can be removed by transient expression of transposases (Yusa et al. 2009). Non-integrating vectors have also 
been used successfully to induce pluripotency. Initial trials involved transduction of mouse cells with 
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adenovirus and non-viral methods including plasmid transfections (Okita et al. 2008, Stadtfeld et al. 2008). 
Adenovirus was later proved to be capable of inducing pluripotency in human dermal fibroblasts as well (Zhou 
et al. 2009). Interestingly, Yamanaka’s group has recently reported a highly efficient reprogramming of human 
dermal fibroblasts and dental pulp cells using episomal vectors carrying the four classical transcription factors 
in addition to L-MYC and P53 shRNA (Okita et al. 2011). Finally, extensive research is being carried out to 
screen for compounds that might permit the process of iPSC induction without the introduction of genetic 
materials (Lin et al. 2009). 
 
Special considerations and technical challenges for iPSC-based neurotoxicological applications 
 
A number of obstacles stand between these promises of iPSC technology and their practical application. This 
review seeks to find a realistic optimism for what can reasonably be accomplished in the coming years as well 
as detail some of the key roadblocks that must be addressed before the hope of such applications can be 
realized. 
 
Generation, maintenance and selection of appropriate iPSCs for toxicity testing 
 
The process of iPSC induction encompasses multiple steps with many possible hurdles. The efficiency of 
reprogramming varies greatly depending on many overlapping technical and biological factors. Although 
different labs report the efficiency of reprogramming in different ways, the overall rates are not satisfactory. 
Indeed, ever since the first human iPSC was made, extensive work has been focused on improving both the 
quality and efficiency of the reprogramming process (Figure 3 (4.1)). Adding small molecules to manipulate 
certain signaling pathways has attracted special attention recently because of the reproducibility and consistency 
of the results. Most commonly, the targets of these attempts are either the epigenetic state of the reprogrammed 
cells or certain cellular pathways responsible for cell growth and fate determination. Certain epigenetic 
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characteristics are particularly pervasive in hESCs, and screening for molecules that alter the epigenetic state of 
the reprogrammed cells has identified some compounds that add to the reprogramming efficiency (Rada-
Iglesias et al. 2011). For example, treating partially reprogrammed cells with the DNA methyltransferase 
inhibitor 5-aza-cytidine (AZA) has been found to both improve the reprogramming efficiency and to induce a 
rapid and stable transition to fully reprogrammed iPSCs (Huangfu et al. 2008, Mikkelsen et al. 2008). Finally, it 
has been shown that iPSC generation is markedly enhanced by p53 gene suppression, and implementation of 
this knowledge dramatically improves reprogramming by episomal vectors (Hong et al. 2009, Okita et al. 
2011). It remains to be determined what impact the choice of reprogramming method may have on 
neurotoxicological outcome measures of neuronal lineages derived from hiPSCs. 
	  
Figure 3 – Generation of human induced pluripotent stem cells for neurotoxicological studies. Schematic 
representation of the generation and differentiation of hiPSCs into mature neurons. Approximate timeline of this 
process are indicated underneath each stage of development. The colored bars indicate the types of toxicological 
assays and the periods in which they can be performed. The circled numerical cross-references adjacent to 
individual steps or experimental paradigms highlight the sub-chapter in the text discussing  specific technical 
challenges. 
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Selection of iPSC lines appropriate for neurotoxicological studies relies on their behavior in culture, validation 
of their pluripotency characteristics (i.e. assessment of their pluripotency), their ability to differentiate with 
good efficiency to the required cell type, and the fidelity of their genome and epigenome. Here we will consider 
the first two points, and we will leave the later points to subsequent sections.  
 
Characterization of pluripotency in iPSC lines has rested heavily on the degree by which they show similarities 
to ESCs in their colony and cellular morphology, molecular and expression characteristics, and their qualitative 
and quantitative capacity to differentiate into the three embryonic germ layers. Research has delineated defining 
characteristics of hESCs that may be used as a reference in the process of pluripotency validation (Initiative et 
al. 2007). Some of these classical characteristics, which are widely used to assess the pluripotency of iPSCs, 
include the expression of certain biomolecular markers such as the tissue-nonspecific alkaline phosphatase, and 
the expression of surface markers specific to pluripotent cells. Examples of these latter markers include TRA-1-
60, SSEA-3 and SSEA-4; and the developmentally regulated genes, like NANOG and OCT4. These classical 
markers, however, are not specific enough to be considered markers for stem cells, as other cell types like 
teratocarcinoma cells also express these same markers (Josephson et al. 2007). Thus, the use of these markers 
alone is insufficient to characterize iPSCs.  
 
The most widely accepted test of pluripotency is the in vivo demonstration of a stem cell line’s competence to 
differentiate into the three embryonic germlayers as a teratoma (Müller et al. 2010). Briefly, iPSCs are injected 
subcutaneously or intramuscularly in an immunocompromised mouse and a few months later teratomas are 
expected to form. These tumors are resected and sectioned for immunohistochemical staining for markers of 
endoderm, mesoderm, and ectoderm. This test is both expensive and time consuming, and the methods of 
performing the test and reporting the results are largely inconsistent (Müller et al. 2010). Moreover, some 
researchers have demonstrated the ability of partially reprogrammed cells and iPSC lines with genetic and 
epigenetic aberrancies to pass the test successfully. This failure to distinguish lines exhibiting normal hESC-like 
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pluripotency marker expression has led some to call for new standards of pluripotency (Dolgin 2010, Williams 
et al. 2011). Furthermore, the inability of this approach to assess pluripotency in a quantitative and high-
throughput manner exacerbates the need for robust methods of selecting lines for further testing. A more 
simplified approach of in vitro differentiation into embryoid bodies and analysis for generation of the three 
embryonic germ layers has been suggested as an alternate validation approach (Boulting et al. 2011, Okita et al. 
2011). An alternative approach to differentiation has been proposed in which new pluripotent lines can be 
compared and contrasted to reference expression maps of 12 hiPSC and 20 hESC lines that were generated to 
enable high-throughput characterization (Bock et al. 2011). This novel approach allows the generation of an 
expression “deviation scorecard” as an indirect quality control measure of pluripotency by finding gene 
expression patterns that uniquely identify high-quality pluripotent lines. These authors sought to confirm their 
findings by comparison to a “lineage scorecard” by assessing lineage-specific expression patterns from 
embryoid bodies derived from their reference set of pluripotent lines. They found that the “lineage scorecard” 
could accurately distinguish biases in differentiation propensity between pluripotent lines and identify lines that 
exhibit impaired differentiation towards neuronal lineages. Such validation has obvious applications in selecting 
lines for neurotoxicity testing by enabling the collection of phenotypically matched hiPSC lines from different 
subjects with similar neuronal differentiation propensities, as well as matched epigenetic and transcriptional 
profiles. Finally, hiPSCs that exhibit a high degree of spontaneous differentiation may need to be excluded – a 
potential explanation for such a phenotype is an inherent instability in maintaining a normal diploid karyotype.  
 
Inconsistency and low-efficiency of neuronal differentiation methods 
 
hiPSCs are in many aspects similar to hESCs and can be differentiated in culture into multiple cell types 
including neurons (Chamberlain et al. 2008, Dimos et al. 2008, Ebert et al. 2009). The availability of robust 
differentiation protocols to generate a variety of neuronal types from hiPSCs is a necessary requirement to 
perform neurotoxicological studies. This is not always the case in practice unfortunately, and accurate 
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assessment of the toxicity of a certain compound is frequently hampered by the inconsistency and/or the 
inefficiency of the differentiation protocol. While this is true for certain neuronal types (e.g. mesencephalic 
dopaminergic neurons), the problem seems sometimes to pertain to the nature of the hiPSC line used in the 
differentiation process rather than the differentiation protocol itself (Hu et al. 2010). One of the important 
factors that causes low efficiency is the persistent reactivation of the latent viruses used in the reprogramming 
process (Papapetrou et al. 2009). However, subsets of hiPSCs generated by integration-free conditions have 
been found to also exhibit low neuronal differentiation efficiencies (Hu et al. 2010).  
 
The process of differentiating hiPSCs to neurons is carried out through successive stages that start with forming 
the neuroectoderm, which marks the early commitment of the stem cells to the neuronal lineage (Figure 3 
(4.2a)) (Muñoz-Sanjuán et al. 2002, Liu et al. 2005). In the absence of external signals hESC-derived 
neuroectoderm inherently differentiates towards dorsal telencephalic progenitors and eventually to cortical 
glutamatergic neurons (Li et al. 2009). In the presence of certain morphogens, however, these neuroectodermal 
cells are further patterned along the ventro-dorsal and rostro-caudal axes forming region-specific progenitors 
(Table 1) that give rise later to fully mature neurons (Li et al. 2009). The time of exposure to these morphogens 
and their concentration are critical factors that determine the fate of neuroectodermal cells. For example, 
exposure to FGF8 before SOX1 upregulation results in the generation of mesencephalic dopaminergic 
progenitors, while forebrain dopaminergic progenitors are typically formed after exposure of SOX1 positive 
cells to FGF8 (Yan et al. 2005). 
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Table 1. Representative protocols for differentiation of hiPSC and hESC to region-specific neuroprogenitors. 
 
Further maturation of regional specific neuroprogenitors to fully mature neurons follows protocols based on the 
same principles of the timely treatment with the right concentration of the appropriate morphogen (Figure 3 
(4.2b)). Many neuronal types have been generated from both hESCs and hiPSCs using several protocols (Table 
2) but the efficiency of making the required cell types is generally low. In addition to that, making terminally 
differentiated neurons consumes a considerable amount of time, and the cost of the different chemicals used in 
the process is not always affordable for academic researchers.
Target Cell 
 
Source 
Cell 
Duration of 
Differentiation 
Comments References 
Neuroectoderm (NE) 
(Pax6+, Sox1+) 
iPSC 
hESC 
1-2 weeks  >80% of stem cells 
become NE cells. iPSC 
exhibit variable 
efficiency  
Hu et al. 2010, PNAS. 
Chambers et al. 2009, 
Nature Biotechnology.  
Telencephalic 
progenitors  
(Pax6+, FoxG1+) 
iPSC 
hESC 
3-4 weeks > 90% of NE cells 
differentiate to this cell 
type 
Zeng et al. 2010, PLoS One. 
Li et al. 2009, 
Development. 
Cortical progenitors 
(Pax6+, Emx1+) 
iPSC 
hESC 
4 weeks Important stage in the 
differentiation to 
glutamatergic neurons 
Li et al. 2009, 
Development. 
Medial ganglionic 
eminence (MGE) 
progenitors  
(Pax6-, Nkx2.1+) 
iPSC 
hESC 
4 weeks Progenitors of 
GABAergic interneurons 
and BFCN 
Li et al. 2009, 
Development. 
Lateral ganglionic 
eminence (LGE) 
progenitors  
(Pax6+, Gsx2+) 
iPSC 
hESC 
4 weeks Progenitors of 
GABAergic projection 
neurons  
Li et al. 2009, Development. 
Aubry et al. 2008, PNAS.  
Midbrain progenitors 
(FoxA2+, En1+) 
iPSC 
hESC 
26 days Early FGF8 treatment is 
essential  
Yan et al. 2005, Stem Cells. 
Hindbrain/Spinal cord 
progenitors  
(Pax6-, Hoxb4+) 
iPSC 
hESC 
17 days Early treatment with 
retinoic acid is essential 
Zeng et al. 2010, PLoS One. 
Li et al. 2008, Stem Cells.  
Multipotent neural 
crest cells 
(p75+, Hnk+, Ap2+) 
iPSC 
hESC 
11 days Cells successfully 
underwent >25 passages 
with retention of 
multipotency 
Menendez et al. 2011, 
PNAS. 
Ventral spinal cord 
progenitors  
(Pax6-, Olig2+) 
iPSC 
hESC 
4 weeks Retinoic acid for 
caudalizing, and SHH for 
ventralizing, are utilized 
Zeng et al. 2010, PLoS One. 
Li et al. 2008, Stem Cells. 
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Table 2. Representative protocols for differentiation of hiPSCs and hESCs to mature neurons. 
 
 
Target Cell Source 
Cell 
Duration of 
Differentiation 
Comments References 
Retinal pigment 
epithelium (RPE) 
cells  
iPSC 
hESC 
8-12 weeks  70-80% of terminal 
differentiated neurons are RPE 
Kokkinaki et al. 2011. 
Stem Cells. Idelson et 
al. 2009, Cell Stem Cell. 
Cortical 
glutamatergic 
neurons  
(VGLUT1+, 
TBR1+) 
iPSC 
hESC 
6 weeks 60-70% of stem cells become 
VGLUT+ even without added 
morphogens 
Zeng et al. 2010, PLoS 
One. Li et al. 2009, 
Development. 
Striatal projection 
GABAergic neurons 
(DARPP32+) 
hESC 9 to 10 weeks The yield is low (22% MAP+, 
of those 36% are GABA+) 
Aubry et al. 2008, 
PNAS.  
Basal forebrain 
cholinergic neurons 
(BFCN) (ChAT+) 
hESC 35-40 days SHH is essential in the 
protocol. Efficiency is high 
(~90% of final neurons) 
Bissonnette et al. 2011, 
Stem Cells. 
Midbrain 
dopaminergic 
neurons  
(TH+, Girk2+) 
iPSC 
hESC 
~40 days TH+ cells form 30-60% of the 
terminal neurons. Generated 
TH+ neurons are functional 
Andrezej Swistowski et 
al. 2010, Stem Cells. 
Myung Soo Cho et al. 
2008, PNAS. 
Forebrain 
dopaminergic 
neurons  
(TH+, GABA+) 
hESC ~40 days Protocol yields 30% GABA+ 
&TH+ neurons in the final 
culture 
Yiping Yan et al. 2005, 
Stem Cells. 
Spinal motor neurons  
(HB9+, ChAT+) 
iPSC 
hESC 
5-8 weeks ~30% of final neurons exhibit 
motor neuron markers 
Li et al. 2005, Nature 
Biotechnology. Hu et al. 
2009, Nature Protocols. 
Karumbayaram et al. 
2009. Stem Cells. 
GABAergic 
interneurons 
    These cells differentiate 
alongside glutamatergic, 
projection GABAergic, and 
basal forebrain cholinergic 
neurons  
Liu and Zhang 2011. 
Cell Mol. Life Sci. 
Astrocytes  
(S100b+, GFAP+) 
iPSC 
hESC 
180 days Almost 90% of final cultures 
cells are astrocytes in these 
protocols.  
Krencik et. al. 2011, 
Nature Biotechnology. 
Oligodendroglial 
cells  
(Olig2+, Nkx2.2+, 
S0x10+, PDGFR+) 
iPSC 
hESC 
4 months Almost 80% of final cultures 
cells are oligodendrocytes 
Hu et al. 2009, Nature 
Protocols. Hu et al. 
2010, PNAS. 
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Recently, fully mature murine neurons have been made by direct conversion of fibroblasts (Vierbuchen et al. 
2010). Following that, attempts have been made to make human neurons based on the same principle, using 
lentiviral vector-based gene delivery system to force the expression of a set of transcription factors peculiar to 
the final cell type. Indeed, fully mature and functional glutamatergic and dopaminergic neurons were made 
directly from fibroblasts, circumventing the intermediate step of iPSCs induction (Table 3, Figure 1 (4.2c)) 
(Caiazzo et al. 2011, Qiang et al. 2011). The generated neurons seem to undergo major epigenetic reset 
expected to occur during such a switch between two terminally differentiated somatic cells. The duration of 
these protocols is significantly short (18 to 21 days) compared to the iPSC-based protocols, but the efficiency of 
making the final neuronal type is still low. Clearly though, direct differentiation methods will not be a viable 
strategy for studies of neurodevelopmental toxicity as the cells bypass the normal neurodevelopmental stages of 
neuralization, specification and maturation. 
 
Table 3. Generation of glutamatergic and dopaminergic neurons by direct conversion from fibroblasts. 
Target Cell Source Cell Duration of 
Differentiation 
Comments References 
Human induced 
neuronal cells 
(hiN) 
Fibroblasts  3 weeks 50-60% of final neuron in culture (~30%) 
were vGLUT1+. Study limited by the 
functionally heterogeneous mutations 
Qiang et al. 
2011, Cell. 
Mesencephalic 
dopaminergic 
neurons 
Fetal and 
adult 
fibroblasts 
18 days Very low yield (10% of final culture 
MAP+ and 6% TH+) 
Caiazzo et al. 
2011, Nature. 
Pfisterer et 
al. 2011. 
PNAS. 
 
To improve the efficiency of the current protocols for neural differentiation of iPSCs, certain measures should 
be considered. Using integration-free iPSC induction methods eliminate the problem of persistent activity of 
viral genome and its negative effect on the differentiation process. Careful and consistent iPSC culture 
techniques are necessary to watch for iPSC lines that exhibit aberrant behavior in culture or are found to have 
abnormal genomes (Neely et al. 2011). Using small molecules inhibitors of Activin/Nodal and BMP signaling 
pathways significantly increases the efficiency of neural differentiation (Chambers et al. 2009, Morizane et al. 
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2011). In fact, the variability and inefficiency of iPSCs to differentiate to the early neuroectodermal stage has 
been effectively overcome by such a regimen (Kim et al. 2010). As mentioned earlier, optimization of the time 
of treatment and concentration of the used morphogens is an absolute requirement for an efficient 
differentiation protocol. Knowledge of such details is greatly enhanced by a parallel understanding of the 
normal development of the nervous system in human embryos.  
 
Measures to reduce the cost and duration of neural differentiation make it possible to perform more 
neurotoxicological experiments on neurons that would otherwise be unaffordable. One strategy has been to 
come up with inexpensive compounds that could substitute for their more expensive counterparts used usually 
in the differentiation process. An example is the replacement of sonic hedgehog, an important neural 
morphogen, by the much cheaper puromorphamine, a purine derivative that activate hedgehog pathway  (Sinha 
et al. 2006). Maintenance and propagation of hiPSC-generated neuroprogenitors that retain the capability to 
differentiate to mature neurons is a viable option to shorten the duration of differentiation and to unify the tested 
neuronal populations (Li et al. 2011). Crypopreservation and later thawing of neurprogenitors could be possible 
as well, although cell death is observed based on the technique and the used freezing medium (Milosevic et al. 
2005). 
 
Exposure paradigms 
 
Perhaps one of the most powerful applications of iPSC technology in the field of neurotoxicology is the ability 
to assess the response of neurons and neural progenitors to various toxicants (Figure 3 (4.3)). Not only can 
many different potentially noxious agents be screened, but also the temporal properties of their administration 
can be used to simulate different patterns of potential human exposure. Many neurotoxicants, methylmercury 
being a prominent example, show both acute and latent effects. Additionally, they can exhibit heightened 
toxicity for specific neurodevelopmental stages, cell types, or time points under either acute or chronic 
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exposures (Weiss et al. 2002, Farina et al. 2011, Ni et al. 2011). One advantage of working with iPSCs is that 
both neural progenitors and terminally differentiated neurons can be assessed. Furthermore, the influence of 
exposure on developing neurons and the adult phenotype of differentiated neurons can be assessed under a 
number of exposure paradigms designed to mimic true environmental exposures within a single experimental 
model. Thus in vitro neuronal differentiation of hiPSCs enables assessment of interactions between early 
exposure and subsequent risk of neurodegenerative phenotypes in response to acute, chronic, latent and multi-
hit toxicant exposure paradigms. A number of toxicants including ethanol, methymercury, PCBs, and cocaine 
have been shown to elicit neurodevelopmental toxicity by disrupting neural stem cell differentiation (Tateno et 
al. 2004, Fritsche et al. 2005, Tamm et al. 2006, Radio et al. 2008). Until the advent of iPSCs, these cell types 
could only be studied through primary culture or ESC derived neural progenitors, which require great effort to 
obtain and are not patient-specific. Thus, the use of hiPSCs is particularly attractive given that differential 
susceptibility of iPSC-derived cells from patients of various genetic backgrounds can be studied. However, it is 
important to note that the in vitro model of iPSC-derived neurons is limited in its capacity to simulate the 
complex extracellular environment, diversity and organization of various neuronal and glial cell types and the 
connectivity and activity of the neural circuitry found in vivo. For example, generation of mixed neuronal-glial 
cultures may be required to accurately model neurotoxicity. This approach would require parallel differentiation 
of stem cells into neuronal and glial lineages followed by co-culturing both cell types at the desired time point 
(Haidet-Phillips et al. 2011).  However, the methods to obtain consistent mixed or single-lineage neuronal or 
neuronal-glial cultures from in vitro differentiation protocols of independent hiPSC lines have yet to be 
achieved. 
 
Chronic toxicity is known to play a substantial role in many neuropathologies. Chronic exposure to the heavy 
metal manganese likely contributes to PD or PD-like pathology in patients (Aschner et al. 2009, Guilarte 2010). 
Acute exposures to manganese are known to produce a subclinical and clinical movement disorder collectively 
referred to as Manganism; but despite similarities between Manganism and PD, the relationship between 
	  32 
chronic manganese exposure and PD remains unclear (Aschner et al. 2009, Lucchini et al. 2009, Guilarte 2010). 
iPSC-derived neurons and neural progenitors may permit the study of chronic heavy metal exposures in 
developing and mature neurons. Such paradigms are useful to study the effect of exposure to a toxicant over a 
long period of time, possibly mimicking the effect of the cumulative toxicity of environmental toxicants on the 
CNS throughout the age of the affected individual. Usually the suspected toxicant is applied at low doses whose 
effect might not be apparent immediately, like the case in acute exposure paradigms, but might eventually 
exhaust the cellular repertoire of defense mechanisms and eventually manifest as a decrease in the number of 
viable neuronal subpopulation and/or altered cellular mechanisms that are crucial for normal function. The 
duration of exposure varies but is often limited by the time required to differentiate stem cells to the desired 
neuronal type. 
 
This approach confers several advantages given that a wide array of cell types can be assessed via toxicological 
assays at several time points. Furthermore, the iPSC approach for chronic exposure toxicity testing is consistent 
with calls to reduce reliance on vertebrate animal models (Buzanska et al. 2009, Harrill et al. 2011). However, a 
major limitation of hiPSC models for studying chronic neurotoxicants is the lack of endogenous detoxification 
mechanisms (e.g. peripheral detoxification mechanisms of the liver, or neuroprotective mechanisms within the 
brain by astrocytes and microglia). The lack of such systems in iPSC-based in vitro differentiation models are 
extremely difficult to appropriately account for experimentally, although they play a major role in modulating 
toxicity in vivo. Thus early applications of hiPSC based models may need to focus on toxicants in which the in 
vivo metabolites are known and their neuronal distribution is understood. As mentioned above, the use of 
neuronal-glial mixed cultures could be achieved – however even here our basic understanding of regional 
differences in how toxicological mechanisms and detoxification pathways differ between discrete regions of the 
brain is insufficient to accurately model the in vivo condition. Nonetheless, cell autonomous mechanisms of 
vulnerability to and protection against chronic neurotoxicants is presently accessible to investigation. Thus 
genetic differences between individuals that mechanistically act at the cellular or molecular level of the target 
	  33 
will provide insight into patient-specific toxicological risk assessment in a manner not presently addressable by 
any other model system. 
 
Finally, iPSCs have limitations in evaluating repeated toxicant exposures over the extended lifespan of a given 
neuronal or glial cell. Although investigators have devised a number of assays to assess pathological processes 
in iPSC-derived neurons, it may be difficult to demonstrate complex phenomena such as hormesis that act over 
extended periods of time and rely on undefined cellular functions or interactions. Work has been performed 
assessing electrophysiological profiles of iPSC-derived neurons, but conclusions regarding repeated exposures 
at a clinically relevant level may be confounded by a number of variables specific to iPSC reprogramming 
(Brennand et al. 2011). Despite these caveats, iPSCs may be able to be used to study phenomena, such as 
preconditioning, in circumstances in which the protective role of an early limited toxicant exposure is not 
dependent on another cell type. The exploration of preconditioning and hormesis is particularly valuable in the 
study of neurodevelopmental toxicity. It has been established that low-levels of oxidative stress can lead to 
hypomethylation and down-regulation of key stress mediators such as heat shock proteins and DNA 
methyltransferases (Shutoh et al. 2009). Whether such mechanisms occur in iPSC-derived neuronal lineages, 
and mimic the conditions that give rise to these mechanisms in vivo, remains to be determined. Nonetheless, 
even if the set point for such mechanisms may differ in vitro from the in vivo condition – human-specific and 
genetic variation-dependent differences in these mechanisms may still be detectable.  
 
Coherence of genotype and phenotype 
 
One of the major challenges with hiPSC models is establishing a clear relationship between genotype and 
phenotype in cells derived from a given patient. It has been previously reported that cell lines derived from 
individual patients can differ based on DNA methylation pattern and variable gene expression (Chin et al. 2009, 
Doi et al. 2009, Stadtfeld et al. 2010, Boulting et al. 2011). This variability is believed to underlie variable 
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efficiencies of neuronal differentiation between iPSC lines. Another confounding factor that could disrupt a 
clear relationship between genotype and phenotype is the presence of reprogramming vectors in virally 
reprogrammed cells. Variability between lines has been difficult to identify early in the differentiation process. 
Furthermore, no direct relationship has been noted between expression of pluripotency markers and 
differentiation capacity (Boulting et al. 2011). Overcoming this difficulty has been addressed by recent work, 
which was able to successfully predict differentiation potential through analysis of epigenetic and 
transcriptional differences between lines (Bock et al. 2011, Boulting et al. 2011). In another comparison of 22 
human iPSC lines, it was revealed that there were an average of five protein-coding point mutations in sampled 
regions (Gore et al. 2011). These mutations consisted of splicing, nonsense, and non-synonymous variants that 
appeared both before and after fibroblast reprogramming (Gore et al. 2011). Similarly, early passage hiPSCs 
were found to contain a significantly higher frequency and degree of mosaicism for copy number variations 
compared to late passage hiPSCs or hESCs (Hussein et al. 2011). These de novo mutations, likely stemming 
from the reprogramming process itself, may obscure genotype-phenotype associations behind this mutational 
noise.  
 
Genetic and epigenetic abnormalities in hiPSCs can arise either during the process of induction or during the 
subsequent culture process (Gore et al. 2011, Hussein et al. 2011, Lister et al. 2011). Genetic abnormalities may 
be at the chromosomal, sub-chromosomal or single-base levels, and their potential occurrence could have 
crucial implications for the appropriate use of iPSCs for research purposes. Some studies have suggested a high 
mutational load present in many hiPSC lines. It has been proposed that whole genome or complete exome 
sequencing may help identify lines with fewer mutational events and eliminate variability between lines (Gore 
et al. 2011). The loss of genetic fidelity may be reflected in aberrancies of cell behavior in tissue culture, 
abnormal morphology, growth rate alteration, and frequent differentiation. While most of the genetic variation 
involves a small subset of cells, there are recurrent mutational events such as trisomy 12 and trisomy 17 that 
convey a selective advantage whereby mutant cells replace euploid population after a few passages (Meisner et 
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al. 2008). It is thus reasonable to check the karyotype and genetic integrity of cultured hiPSCs for abnormalities 
at regular intervals; though at a significant added expense for research laboratories. 
 
Appropriate modeling of epigenetic influence and ‘residual epigenetic marks’ 
 
Epigentic state is known to have a powerful influence on chemical toxicity (LeBaron et al. 2010, Fragou et al. 
2011, Perera et al. 2011). Thus an important consideration in the application of iPSC technology in the study of 
neurotoxicology is the status of epigenetic modifications such as genomic DNA methylation and histone 
modifications (Figure 3 (4.5)). Given the critical role of epigentic state in development and differentiation, 
understanding the epigenetic profiles of hiPSCs is an important component to validating patient-specific 
experimental findings. The induction of somatic cells to iPSCs is known to alter their epigenetic profile 
(Guenther et al. 2010). The iPSC epigenetic profile, while similar to that of ESCs, has notable characteristic 
features. These epigenetic modifications can have a significant influence on the ability of iPSCs to differentiate 
into various cellular subtypes (Kim et al. 2010). In order to generate a greater understanding of the nature of the 
unique epigenetic profile of iPSCs, a recent study generated a whole-genome single-base resolution DNA 
“methylome” via bisulphite sequencing (Lister et al. 2011). Investigators found that iPSC lines were methylated 
at CG dinucleotide pairs at a higher frequency than somatic cells, in a manner similar to that of ESCs (Lister et 
al. 2011). Furthermore, upon comparison of the methylomes of iPSCs with that of ESCs, notable unique 
methylation loci were identified between cell types. One challenge when analyzing iPSC epigenetics is 
distinguishing between methylated regions that are vestiges of the somatic cell from which they are derived and 
those that result directly from reprogramming. It has been established that low-passage number iPSCs contain 
DNA methylation signatures derived from the tissue of origin (Kim et al. 2010). Many of these methylated 
regions are shared between individual iPSC lines, suggesting certain loci have an increased susceptibility to de 
novo methylation (Lister et al. 2011). Potentially, these high susceptibility regions can be monitored for 
stochastic methylation, a valuable tool when characterizing the efficiency of reprogramming and differentiation 
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of a given line (Lister et al. 2011). Interestingly, a recent study has noted that iPSCs methylation patterns 
become similar to ESCs with each sequential passage number (Nishino et al. 2011). The mechanism of this 
methylation is thought to be the result of the convergence of stochastic de novo hyper-methylation in adjacent 
genomic regions (Nishino et al. 2011). As the mechanisms of de novo methylation become revealed, 
interventions with chromatin-modifying drugs have the potential to address these concerns. Furthermore, given 
that fibroblasts are a common somatic tissue source, the methylation profile of iPSCs used in neurotoxicological 
assays may need to be standardized before disease modeling of neurological disease can be directly comparable 
between studies.  
 
Undefined modifiers of toxicity 
 
Perhaps one of the greatest challenges in applying iPSC technology to the field of neurotoxicology is replicating 
the toxicological conditions that reflect the insults arising in vivo from actual environmental exposures. 
Influences due to the specific route of exposure, interactions with other toxicants and environmental modifiers, 
as well as previous exposures, nutritional state, or chronic illness of the individual are currently difficult to 
account for using in vitro models, including differentiated neuronal lineages of hiPSCs. Furthermore, the 
actions of such undefined modifiers of toxicity may occur across diverse temporal and spatial axes (Figure 3 
(4.6)). Thus the environmental, anatomical and developmental history of the primary target cell of a toxicant 
may be influenced by previous exposures, nutritional state, and status of support tissues or neuronal 
connectivity that is challenging to model in vitro. Furthermore, this issue is complicated by potential differences 
in the epigenetic status of iPSC derived cells that may not reflect the in vivo epigenetic state of the intended 
neuronal populations being modeled from the individual or human population being studied. The multi-factorial 
and synergistic potential of unknown modifiers to influence both the type and magnitude of toxicological 
outcomes are likely critical to actual disease etiology. Furthermore, it is often of particular interest to examine 
the role of neurotoxicants under specific disease states. Similar spatial, temporal, and anatomic constraints 
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impact neurological disease modeling by hiPSCs as well (Saha et al. 2009). Thus undefined modifiers of 
neurotoxicity are layered upon the additional complexities of in vitro disease modeling. However, it should be 
pointed out that similar challenges in interpreting experimental data apply to most model systems.  
 
At the present state, effort should be directed toward standardization of iPSC phenotypes and development of 
adequate controls and appropriate validation of experimental results. For example, iPSCs derived from 
unaffected siblings are valuable controls as they generally have a similar environmental and genetic background 
as the patient. Thus, experimental differences in the sensitivity of phenotypic outcomes to toxicant exposure of 
differentiated or differentiating neuronal cells are more likely due to known genetic or epigenetic differences 
between the subjects. Furthermore, multiple lines should be generated from each subject to account for the 
inherent variability between individual lines.  
 
Aging and senescence is also an important concern when generating iPSCs. It has been established that 
fibroblasts derived from older mice have lower efficiency of reprogramming (Li et al. 2009). This may be 
mediated by expressions of genes related to senescence such as the Ink4b/Arf locus, which is upregulated in 
biological aging. It has been demonstrated that the generation of iPSC lines from older patients can be improved 
by inhibiting senescence with siRNAs, treating somatic cells with antioxidants, or reprogramming in low-
oxygen conditions (Utikal et al. 2009, Yoshida et al. 2009, Banito et al. 2010, Esteban et al. 2010). An 
important question, particularly in the study of neurodegenerative diseases, is whether aging can be reproduced 
in iPSC-derived cells. Reprogramming of fibroblasts into iPSCs is thought to reset markers of cellular age such 
as telomere length (Suhr et al. 2010). This change in telomere length is transient however, as telomere 
shortening was observed in iPSC-derived cells after differentiation (Suhr et al. 2010). Similarly, it has been 
established that the “energetic capacity” of cells can be reset through reprogramming, by reestablishing 
mitochondrial compliment to a neonatal-like state (Suhr et al. 2010). As mitochondrial capacity decreases with 
aging largely due to oxidative stress, these findings suggest that future studies utilizing iPSCs may focus on 
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replicating the cellular state of older subjects through prior exposure to reactive oxygen species. Nutritional 
variables could also be addressed with a similar approach; simultaneous treatment with naturally occurring 
antioxidants or chronic alcohol exposure could give insight into neuroprotective or neurotoxic roles of various 
substances. Upon further standardization of patient derived iPSCs, disease-modifying variables such as 
developmental history, early-life environmental exposures, epigenetic status, nutritional state, and age may be 
able to be accounted for in toxicological studies. 
 
Challenges of scale 
 
In the area of neurotoxicology, iPSCs can help address questions regarding why individuals with similar genetic 
backgrounds demonstrate differential susceptibility to toxicants. But before hiPSC-based neurotoxicological 
approaches can be broadly applied for toxicological risk assessment and in depth patient-based mechanistic and 
neuroprotective studies the critical hurdles of high cost and poor scalability associated with maintenance and 
analysis of multiple hiPSC lines simultaneously must be addressed. Significant person-hours are required to 
reprogram, validate, differentiate, and toxicologically assess multiple cell lines from just a single patient. 
Consequently, a seemingly straightforward study seeking to explore differences between patients with a given 
mutation and controls can easily become overwhelming for even a moderately sized research group. Thus, 
studies using hiPSCs remain quite low-throughput at present time, with recent published data comparing simple 
measures in no more than 10-20 lines, and even fewer lines for more complex phenotypic analysis. But 
significant improvements may be within reach by use of robotic automation and more efficient methodology 
(Dolmetsch et al. 2011). Perhaps the two disciplines that would benefit most from high-throughput hiPSC 
development are drug development and toxicology. For example, drug screening would require sufficient cells 
and sample size such that thousands of compounds could be screened (Ellis et al. 2011).  
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Modern tissue culture protocols are both time consuming and have tremendous batch-batch variability that may 
influence downstream assays. One recently proposed approach is the wide-scale utilization of stirred suspension 
bioreactors, which dramatically reduce cost and increase yield of expansion 58-fold (Shafa et al. 2011). iPSCs 
generated in stirred suspension bioreactors retain all pluripotency markers and are able to differentiate into all 
germ layers. However the aggregation into multicellular structures that occur under this approach will require 
adaptation to neuronal differentiation and neural specification methods that use monolayer iPSC cultures as 
their starting point. This approach has yet to be widely adapted in research laboratories owing to its high costs 
and specialized equipment, but may represent an important step toward high-throughput assays and 
commercialization of iPSCs.  
 
Issues regarding scalability are an active area of discussion as it hinders collaboration between research groups. 
These issues include: reproducibility of protocols, cell line nomenclature, intellectual property issues, and lack 
of a detailed and centralized database of available hiPSC lines (Luong et al. 2011). There is a strong demand 
within the field to establish an iPSC library in conjunction with a clinical database, tissue bank, and genome 
wide association studies (GWAS) (Hankowski et al. 2011). Such a database would address concerns regarding 
reproducibility and nomenclature, making data directly comparable across studies. 
 
The rapid development of hiPSC technology has benefited tremendously from the tailwind of hESC research. 
Aside from the unique reprogramming method, the reagents, differentiation protocols, and media are near 
identical to that of hESCs. However, the patient-specific nature of hiPSCs has generated a new demand for 
scaling up these protocols in a high-throughput manner. Thus, current cost-constraints and difficulties in cross-
institutional collaboration will likely spur rapid innovation in scalability in the near future. This positive outlook 
of high-throughput screening utilizing iPSCs should incentivize investigators interested in toxicological 
assessment of neurological disease to adapt this technology as soon as possible. 
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The potential hiPSC technology for personalized medicine and risk assessment 
 
As discussed above, hiPSCs have a wide-range of potential clinical applications, particularly in the field of 
personalized medicine. These applications include generation of cells for transplantation therapy and as a model 
of human disease (Hankowski et al. 2011). The major advantage of iPSCs over other disease models is that it 
has the potential to model any disease and toxicological phenotype, especially those that do not currently have 
an animal model. Furthermore, hiPSCs permit the study of diseases that are both genetic and environmental in 
nature. Thus, for the first time, the study of gene-environment interactions utilizing cellular subtypes derived 
from patients afflicted with a given illness is possible. Data derived from such studies in the future may provide 
a critical translational link between model organism-based, computational, and in vitro toxicological data to 
epidemiological and other human population studies. Furthermore, this approach is not solely for learning more 
about disease pathogenesis, but may be directly utilized in clinical practice. For example, by using patient-
specific iPSC-derived neurons to customize neuroprotective strategies and environmental safety information for 
individuals. These future applications may also include direct transplantation of patient derived cells, toxicity 
studies, and drug efficacy and safety evaluations.  
 
A lofty but often stated goal for hiPSC technology is its potential to provide personalized neurotoxicological 
risk assessment. For example, iPSC lines generated from an individual may enable assessment of individualized 
sensitivities to common environmental pollutants enabling targeted prophylactic measures. Likewise, 
assessment of heightened sensitivity to particular common toxicological insults (e.g. oxidative stress, 
mitochondrial dysfunction, protein misfolding, calcium handling deficits) may enable personalized 
neuroprotective strategies to be derived and prescribed. However, a measure of skepticism is warranted given 
the novelty of iPSC-associated approaches.  
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hiPSC technology has the potential to accelerate the pace of drug discovery and improve understanding of 
disease pathogenesis. Clinical, genetic and exposure history data of patients for which hiPSC are generated is 
especially relevant and should be collected as thoroughly as possible, abiding by IRB and HIPPA regulations to 
protect patients’ privacy (Hankowski et al. 2011). Disease modeling using hiPSCs has already shown promise 
given recent success modeling RETT syndrome, Alzheimers disease, neuronal lysosomal disorders, 
Amyotrophic lateral sclerosis, schizophrenia, Parkinson’s Disease and others (Marchetto et al. 2010, Brennand 
et al. 2011, Lemonnier et al. 2011, Marchetto et al. 2011, Seibler et al. 2011, Yagi et al. 2011). In the field of 
drug discovery, iPSCs have the ability to fill the information not covered by genome-wide association studies 
and databases. For example, novel compounds can be screened on mature cells derived from iPSCs generated 
from patients with a given illness. Through this approach, both a toxicity and efficacy profile for a given 
therapeutic agent can be generated (Hankowski et al. 2011). 
 
Similarly, toxicity phenotypes can be studied in vitro by exposing iPSC-derived neurons to various toxicants 
and inflammatory factors (Marchetto et al. 2010, Wichterle et al. 2010, Inoue et al. 2011). Utilization of hiPSC-
based toxicity testing for drug development, includes the promise of developing high-throughput assays 
utilizing iPSC-derived hepatocytes to examine the metabolism of novel compounds (Laustriat et al. 2010, Inoue 
et al. 2011). The effects of aging on disease-toxicity relationships may be challenging to model given that iPSC-
derived cells present from the early stages of development. Future efforts can be directed towards inducing 
cellular injury and metabolic changes that simulate the effects of aging in this process. Although iPSCs show 
promise in the study of neurological disease, one must acknowledge the difficulty of validating iPSC models of 
psychiatric illness. Since disorders such as schizophrenia, autism, and depression have a poorly understood 
molecular and cellular basis, investigators will face difficulty defining which iPSC-derived neuronal lines 
demonstrate the disease-specific phenotype (Dolmetsch et al. 2011).  
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Conclusions 
 
The ability of iPSC lines to be isolated from patients with any neurological disease provides an important tool 
for characterization of susceptibility to various toxicants. Neurotoxicological studies of iPSC-derived cells are 
readily adaptable to existing toxicity assays, which allows experiments to be controlled against primary 
neuronal cultures. Validation of iPSC-based findings will likely be dependent on appropriate validation of the 
iPSCs themselves. For example, expressions of surface markers of pluripotency markers after reprogramming 
and lineage specific markers during differentiation by immunocytochemistry or flow cytometry are critical 
validation steps (Vojnits et al. 2010). One of the foremost challenges facing neurotoxicological application is 
residual epigenetic signatures from reprogramming. Another challenge is the heterogeneous nature of cell types 
generated during differentiation (Anson et al. 2011). Ultimately, these concerns regarding the quality of the 
iPSC models necessitate that resulting neurotoxicological findings be validated in other model systems. Should 
a differential susceptibility to a neurotoxicant be identified in iPSC-derived cells, these results will need to be 
supported by epidemiological, animal, and human studies for the conclusion to be deemed valid.  
 
The translational value of iPSC-based studies may be helped by identification of the key determinants and 
markers of the experimentally introduced genetic and epigenetic differences that contribute to measurable 
toxicological and phenotypic variation between iPSC lines and their derivatives. Controlling for these 
differences in the iPSC lines used for studies should minimize experimental noise and increase the coherence of 
human genotype – phenotype correlations.  At present, since the impact of such experimental variation is 
currently unmeasured – it remains to be seen the numbers of iPSC lines per subject or the numbers of subjects 
needed to have sufficient statistical power to draw meaningful conclusions in neurotoxicological studies. 
However, as more studies are reported in the literature, a meta-analysis could be performed to evaluate these 
features and inform experimental design. One important caveat of iPSC-based neurotoxicological assays is the 
inability to completely model the in vivo neuronal environment, including the spectrum of neuronal network 
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connections and glial interactions.  Thus at present only toxicological phenotypes that can be modeled in a cell 
autonomous manner, or perhaps simplistic mutlicellular models, are likely to provide meaningful information. 
Toxicities that depend on multi-regional interactions between brain regions or the periphery are not likely to be 
captured by iPSC-based modeling. However, when suitable iPSC-based neurotoxicological assays can be 
designed such systems may be uniquely powered as a translatable screening tool to inform and guide resources 
for appropriate human and animal model in vivo studies.
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CHAPTER IV 
 
OPTIMIZATION OF FLUORESCENCE ASSAY OF CELLULAR MANGANESE STATUS FOR 
HIGH THROUGHPUT SCREENING2 
 
Abstract 
 
The advent of high throughput screening (HTS) technology permits identification of compounds that influence 
various cellular phenotypes. However, screening for small molecule chemical modifiers of neurotoxicants has 
been limited by the scalability of existing phenotyping assays. Furthermore, the adaptation of existing cellular 
assays to HTS format requires substantial modification of experimental parameters and analysis methodology to 
meet the necessary statistical requirements. Here we describe the successful optimization of the Cellular Fura-2 
Manganese Extraction Assay (CFMEA) for HTS. By optimizing cellular density, manganese (Mn) exposure 
conditions, and extraction parameters, the sensitivity and dynamic range of the fura-2 Mn response was 
enhanced to permit detection of positive and negative modulators of cellular manganese status. Finally, we 
quantify and report strategies to control sources of intra- and inter-plate variability by batch level and plate-
geometric level analysis. Our goal is to enable HTS with the CFMEA to identify novel modulators of Mn 
transport. 
 
 
 
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
2 Reprinted from Journal of Biochemical and Molecular Toxicology, 27, Kevin K. Kumar, Asad A. Aboud, 
Devin K. Patel, Michael Aschner, Aaron B. Bowman, Optimization of Fluorescence Assay of Cellular 
Manganese Status for High Throughput Screening, 42-9, Copyright (2012), with permission from Wiley 
Periodicals, Inc.	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Introduction 
 
Manganese (Mn) is an environmentally abundant metal that serves as a critical cofactor for numerous enzymes 
such as glutamine synthetase, SOD2, and arginase. Despite active research into the physiological regulation of 
cellular and tissue Mn levels, this process is not fully understood. Mn is believed to primarily enter the central 
nervous system (CNS) across the capillary endothelium at normal physiological concentrations (Aschner et al. 
2007). In addition, at high blood concentrations, transport across the choroid plexus dominates (Murphy et al. 
1991, Rabin et al. 1993, Aschner et al. 2007). Mn transport across the blood-brain barrier involves a diverse set 
of cellular mechanisms including facilitated diffusion and active transport. Greater understanding of Mn 
transport has profound clinical relevance, given that Mn has neurotoxic properties that cause debilitating 
neurological and psychiatric pathologies such as manganism, a condition with features similar to Parkinson’s 
Disease (Aschner et al. 2009). Furthermore, the integral use of Mn in manufacturing sectors such as welding, 
oil refinement, and glass production increase the potential of excess Mn exposure in industrialized nations 
(Bowman et al. 2011). In addition, there have been few advances in therapeutics that protect against Mn influx 
into neurons or promote efflux of the metal once it enters. Although variably effective, chelation therapy with 
ethylenediaminetetraacetic acid (EDTA) or 4-aminosalicylic acid and treatment with levodopa are currently the 
only therapeutic interventions for Mn toxicity (Crossgrove et al. 2004). Despite the critical need to study Mn 
transport, one of the greatest limitations in the study of this process has been the development of novel assays 
that have the potential to be scaled for high throughput screening (HTS). 
 
Our group has previously developed the Cellular Fura-2 Manganese Extraction Assay (CFMEA) to quantify 
intracellular Mn concentrations (Kwakye et al. 2011, Kwakye et al. 2011). CFMEA indirectly measures total 
cellular Mn content via its quenching of fura-2 fluorescence by Mn2+. The fura-2 isosbestic point for calcium 
(Ex360/Em535) is used to avoid interference by cellular Ca2+ ions. This assay permits the highly accurate 
assessment of extracted Mn levels over a range of 0.1-10µM. 
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The advent of HTS, the interrogation of large chemical libraries in the context of a biological target to identify 
active compounds, has been a critical advance in the process of drug development and identification of 
pharmacological candidates for translational applications (Johnston et al. 2002). Although variability within 
routine laboratory assays can be accounted for by performing technical and biological replicates, reliable single-
sample assays are critical for successful high throughput screens. As a result, assays must be optimized for a 
highly robust yet consistent response. Cell-based assay optimization is multi-factorial; including cell density, 
exposure time, compound concentration, assay reagent concentration, and extraction volume. The goal of this 
optimization process is to achieve a Z-factor greater than 0.5 (a statistical parameter that accounts for the signal 
dynamic range and data variation of signal measurements) (Zhang et al. 1999). 
 
Here our ultimate goal is to apply the CFMEA for HTS to permit the identification of small molecule modifiers 
of cellular Mn transport and storage. Given its ease of scalability, culture requirements, and previous success 
measuring Mn homeostasis, we have selected an immortalized murine striatal neuron cell line for these studies. 
One of the greatest challenges in converting a cellular assay into HTS format is limiting the influence of 
confounding variables on the output response. Thus, we sought to accomplish three goals: (1) determination of 
the experimental conditions that elicit approximately 50% quenching of fura-2 signal, (2) characterization of 
plate-based geometric variability and batch-to-batch variability across varying Mn exposure levels, and (3) 
statistical evaluation of the suitability of the CFMEA as an HTS assay. By accomplishing these stated 
objectives, we hope to identify sources of variability inherent in this assay and propose analytical techniques to 
limit their influence. Furthermore, we hope that the process adapting the CFMEA for HTS will be directly 
applicable toward developing other cellular plate-based assays.  
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Results 
 
Determination of optimal cellular density and exposure time 
 
In an initial pilot study using 96-well plates to determine the optimal cell density and exposure time for HTS 
was performed utilizing the wild-type STHdhQ7/Q7 murine striatal cells. Three physiologically relevant Mn 
concentrations were tested plus a vehicle control (0µM, 25µM, 50µM, and 100µM) to determine a condition 
that produced 50% quenching of the vehicle fura-2 signal at a concentration of 0.5µM fura-2. This 
concentration of fura-2 had been shown in the original assay development of CFMEA to be optimal for 
quantification of cellular Mn levels (Kwakye et al. 2011, Kwakye et al. 2011). Concurrently, four different cell 
counts were tested (5000, 7500, 10000, 20000 cells/well) under each of the exposure conditions (Figure 4). To 
evaluate the degree of fluorescence quenching all values are normalized to the fluorescence on the vehicle 
control (%Veh). The data indicate that multiple conditions satisfied our assay goals, such as achieving a 
50%Veh signal and non-overlapping of SD between adjacent concentrations (+/- 1SD). However, both 
conditions were only achieved upon 60-minute exposure of 100µM Mn at either 10,000 or 20,000 cells/well 
(Figure 4). To enhance the scalability of this assay, we utilized the lower cellular density (10,000 cells/well) as 
it also displayed a smaller degree of experimental error suggesting that higher cell densities may exhibit greater 
experimental noise. This set-up served as a basis for further optimizations to reduce variability and modulate 
fura-2 response. 
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Figure 4 – Determination of optimal cellular density and exposure time of CFMEA. Data are presented as 
%Veh vs. exposure time (min) and sorted by plated cell density and Mn exposure concentration (µM). n=4 for 
each condition. Arrows indicate exposure conditions that produced approximately 50% quenching of fura-2 
signal. 
 
Evaluation of optimal fura-2 concentration, extraction volume, and analysis method 
 
Utilizing the aforementioned cell density and exposure conditions (60-minute, 100µM Mn exposure and a 
plating density of 10,000 cells/well in a 96-well plate), a series of experiments were conducted to evaluate 
whether well-to-well variability (i.e. changes in fura-2 signal between replicates across plate regions) could be 
minimized while maintaining a robust response in the dynamic range. Under the hypothesis that optimizing the 
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concentration of fura-2 could enhance the sensitivity of the assay and decrease statistical noise, we sought to 
explore the impact of concentration changes on variability. Varying the concentration of fura-2 (0.25µM, 
0.50µM, 0.75µM) and normalizing the fluorescence quenching by adjusting to %Veh we determined that 
variance (SD) was minimized with 0.75µM fura-2 (Figure 5A). In a similar fashion, we also explored the 
impact of extraction volume on the sensitivity of CFMEA with the goal of achieving near 50 %Veh while 
minimizing error. The extraction volume for CFMEA was varied between 75µL, 100µL, and 125µL reported in 
raw fluorescence values (Figure 5B), indicating the highest signal intensity with 125µL. Subsequently, to 
determine the ideal method to analyze data for HTS using CFMEA, the raw fluorescence values were used to 
derive %Veh and [Mn] extracted values (Figure 5C,D) respectively (Kwakye et al. 2011, Kwakye et al. 2011). 
These results indicated that the higher extraction volume (125µL) resulted in slightly greater precision (smaller 
SD values) across all three quantitative approaches presented here.  
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Figure 5 – Optimization of fura-2 concentration and extraction volume. (A) Fura-2 concentration 
optimization. Data are presented as %Veh vs. concentration of fura-2 (µM) across multiple Mn exposure 
concentrations (µM), n=8 for each condition. (B-D) Extraction volume optimization using 0.75µM fura-2. (B) 
Data are presented as raw fluorescence (Fluor.) vs. volume of fura-2 (µL) across multiple Mn exposure 
concentrations (µM). n=24 for each condition. (C) Extraction volume optimization (%Veh). Data are presented 
as %Veh vs. volume of fura-2 (µL) across multiple Mn exposure concentrations (µM). n=24 for each condition. 
(D) Extraction Volume Optimization (Mn). Data are presented as concentration of Mn extracted (nM) vs. 
volume of fura-2 (µL) across multiple Mn exposure concentrations (µM). n=24 for each condition. (A-D) 
Bracketed bars indicate selected fura-2 concentration and extraction volume data for subsequent downstream 
assays. 	  
Based on the newly optimized fura-2 concentration of 0.75µM for HTS, a new in vitro (cell-free) standard curve 
was generated (Figure 6) to determine the Mn concentration that yields a 50% signal relative to vehicle to 
ensure the highest sensitivity for changes in Mn levels. The target sample response of approximately 50% 
quenching of the fura-2 signal maximizes the detection of both positive and negative modulators of cellular Mn 
status. This mirrors a common approach utilized in activity based in vitro assays that utilize the half-maximal 
activity concentration, AC50, as an output (Inglese et al. 2006). As a result, for a given increase or decrease in 
Mn extracted by CFMEA, there would be the greatest change in fluorescence. 
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Figure 6 – 0.75µM fura-2 standard curve. Data are presented as %relative to vehicle vs. concentration of Mn 
(nM). n=4 for each concentration. 
 
Examination of geometric and batch-to-batch variability 
 
Based on the optimal fura-2 concentration of 0.75µM, a series of experiments was conducted to evaluate the 
inherent geometric variability within a plate (horizontal and vertical) and across experimental batches. A batch 
is defined as the series of plates in which cells were plated, exposed to Mn, and CFMEA performed 
concurrently. Cells grown in 96-well plates were treated with vehicle, 25µM, 100µM, and 500µM Mn for one 
hour and analyzed by both raw fluorescence and %Veh (Figure 7A). In order to segregate major sources of 
geometric variability, cells were plated vertically while Mn exposures and fura-2 extraction buffer were 
delivered horizontally by multi-channel pipetting (Supplemental Figure 2). In addition, three batches consisting 
of multiple plates were analyzed independently and are identified here in downstream analyses by batch and 
plate number (e.g. 1.3 denotes Batch 1, Plate 3). Examination of plate geometric variability by fluorescence 
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revealed pronounced horizontal-related effects, with corresponding decreases and sharp increases within 
particular plates. For example, plate 2.4 exhibited a decreased level of fluorescence in horizontal rows G-H, 
while there was a noticeable increase in fluorescence in row G-H of plate 3.4. Analysis by fluorescence also 
revealed a striking batch-to-batch variability with Batch 1 exhibiting higher overall levels of fluorescence 
compared to Batches 2 and 3. Interestingly, this effect was less noticeable as the Mn exposure concentration 
increased, suggesting that the levels of Mn extracted influence variability of the CFMEA. Based on these 
observations, we suspect that the primary sources of geometric variability are caused by differences in 
extraction buffer volume delivery. 
 
The amount of variability observed by analyzing raw fluorescence values guided us to explore whether this 
phenomenon could be accounted for by normalizing to %Veh (Figure 7A). After reanalyzing by this alternative 
quantitative methodology, there was a substantial decrease in overall variability. Importantly, this method of 
analysis appeared to eliminate batch-to-batch variability, but individual plates still retained some horizontal 
variability. This suggests that differences in the baseline fluorescence of the fura-2 solution prepared for each 
batch was a major source of variability between batches. In order to further evaluate the change in variability by 
standardizing to %Veh, we calculated a normalized SD (for %Veh values versus fluorescence values), which 
adjusted the scale of the SD of each horizontal row to the average SD of all horizontal rows of a given exposure. 
This was necessary since the magnitude of SD values is directly related to the magnitude of the measurements 
themselves. By normalizing the mean fura-2 signal for a given exposure condition within each plate to the 
respective mean fura-2 signal of all rows, of that given exposure condition, across the entire experimental set 
(all plates, all batches) we could compare the degree of variance independent of differences in the magnitude of 
the measured values themselves. Specifically, the mean fura-2 signal values for each plate (fluorescence or 
%Veh) for a given exposure (25µM, 100µM or 500µM Mn) was divided by overall mean signal of every row of 
every experimental plate at that exposure level, generating a normalized mean signal of each row. Calculation 
of the SD of these normalized row values for each experimental plate (i.e. the normalized SD) effectively 
	  53 
allowed direct comparison of the relative magnitude of experimental variation across all plates irrespective of 
exposure condition. These average normalized SD values for all rows of a given exposure for each plate were 
plotted and color coded by batch and compared between analytical methods (fluorescence versus %Veh; Figure 
7B). The normalized SD plot revealed that batch-to-batch variability was controlled by quantitative 
measurements accounting for %Veh. Interestingly, when the dataset was analyzed for vertical-based variability 
across plate region (left, middle, right column groups), there was substantially less variability across the vertical 
axis of the plate relative to the horizontal-dependent variability (data not shown). In agreement with the 
horizontal analysis, a similar pattern of batch-to-batch variability as observed in the vertical-based analysis.
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Figure 7 – Sources of variability and analytical technique. (A) Examination of plate-based geometric and 
batch-to-batch variability. Data are presented in three-dimensional surface plots showing raw 
fluorescence/percent relative to vehicle (Y-axis), by each batch/plate number (X-axis; e.g. 1.2 is plate 2 of batch 
1), by the eight horizontal row positions of each plate (Z-axis; rows A-H). Coloration within the surface plot 
indicates demarcated value ranges along the Y-axis. Separate graphs were generated for each Mn exposure 
(µM) and analysis method (Fluorescence vs. %Relative to Vehicle). n=8 for each condition. (B) Impact of 
analysis method on normalized SD. Data are presented as normalized SD vs. analysis method (Fluorescence vs. 
%Relative to Vehicle). Separate plots were generated for each Mn exposure (µM). n=8 for each condition.
	  55 
Assessment of HTS adaptability of the CFMEA for HTS 
 
In the final phase of this study, we sought to calculate the Z-factor of each plate to assess whether CFMEA 
could be utilized for HTS. The Z-factor was calculated between each of the tested concentrations (vehicle, 
25µM, 100µM, and 500µM Mn). The optimal scores were the Z-factors between vehicle and 500µM Mn, as 
presented (Table 4).  
 
Table 4. Z-factors by batch and plate. 
Batch Plate Z-Factor HTS Quality 
1 1 0.73 Excellent 
1 2 0.73 Excellent 
1 3 0.36 Borderline 
2 1 0.27 Borderline 
2 2 0.40 Borderline 
2 3 0.50 Excellent 
2 4 -0.66 Poor 
3 1 0.47 Borderline 
3 2 0.51 Excellent 
3 3 0.38 Borderline 
3 4 -0.93 Poor 
 
Z-factors were evaluated for HTS based on the following criteria: Z>0.5 was classified as excellent, 0<Z<0.5 as 
borderline, and <0 as poor. Based on these standards, 4 of 11 plates were classified as excellent, 5 of 11 plates 
as borderline, and 2 of 11 as poor. The high proportion of plates classified as borderline or poor was not 
unexpected, given that these pilot assays were conducted by manual liquid dispensing. Utilization of an 
automated pipetting process should substantially reduce variability; thus we sought to explore if controlling for 
the observed horizontal variation would improve the Z-factors for the plates with poor or borderline Z-factors. 
As a proof of principle, plate 2.4 which originally had a Z-factor of -0.66, was separated in two areas (rows A-C 
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and D-H). Using this independent analysis, the Z-factor of each area was improved to 0.42 and 0.45 
respectively.  
 
In the final phase of this study, we sought to calculate the Z-factor of each plate to assess whether CFMEA 
could be utilized for HTS. The Z-factor was calculated between each of the tested concentrations (vehicle, 
25µM, 100µM, and 500µM Mn). The optimal scores were the Z-factors between vehicle and 500µM Mn, as 
presented (Table 4). Z-factors were evaluated for HTS based on the following criteria: Z>0.5 was classified as 
excellent, 0<Z<0.5 as borderline, and <0 as poor. Based on these standards, 4 of 11 plates were classified as 
excellent, 5 of 11 plates as borderline, and 2 of 11 as poor. The high proportion of plates classified as borderline 
or poor was not unexpected, given that these pilot assays were conducted by manual liquid dispensing. 
Utilization of an automated pipetting process should substantially reduce variability; thus we sought to explore 
if controlling for the observed horizontal variation would improve the Z-factors for the plates with poor or 
borderline Z-factors. As a proof of principle, plate 2.4 which originally had a Z-factor of -0.66, was separated in 
two areas (rows A-C and D-H). Using this independent analysis, the Z-factor of each area was improved to 0.42 
and 0.45 respectively. 
 
Discussion 
 
Using the described systematic approach we have optimized conditions of the CFMEA for HTS. In this process, 
we targeted specific technical and theoretical aspects of the assay in an effort to ensure a consistent and robust 
response to changes in cellular Mn status. Importantly, it must be noted that each of these pilot assays was 
conducted manually (e.g. manual liquid exchange and plating of cells). Since HTS is conducted using 
automated robotic delivery and handling systems, we expect the level of overall variability to decrease 
substantially in subsequent assays and by inference the accuracy in identifying modifiers of cellular Mn status 
to increase. Specifically, this conservative approach, one with inherently greater error, suggests that Z-factors in 
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the borderline range will likely improve into the excellent category after automation. In addition, we determined 
that some systematic errors, such as horizontal-dependent variability, could be accounted for by independently 
analyzing the plate along clear demarcated borders in signal response. 
 
Further analyses explored the sources of geometric variability, changes in signal across vertical regions and 
across horizontal rows solely due to location and not experimental manipulation. By originally plating cells 
vertically and delivering all subsequent washes, exposures, and fura-2 extraction buffer horizontally, we have 
identified potential sources of this variability. The minimal level of vertical variability suggests that differences 
in cell density and growth were not a major contributor to intra-plate variability. In contrast, the high level of 
horizontal variability observed could be attributed to differences in the aforementioned deliveries that were 
administered in a horizontal-specific manner. Thus, we recommend that future HTS adaptation record and 
carefully design delivery patterns of solutions, permitting detection of sources contributing to geometric 
variability. 
 
As previously mentioned, HTS does not have the luxury of sample replicates and is performed over a period of 
weeks to months. As a result, these systemic forms of variation must be minimized during this process and 
accounted for during downstream analyses. As a final point, all optimizations for HTS are targeted to achieve 
the threshold Z-factor of 0.5, maximizing confidence in candidate small molecules identified by HTS with this 
method by decreasing the rate of false positive and false negatives. 
 
Furthermore, we discovered that the quantitative method of analysis is critical to account for batch-to-batch 
variability. The observed signal variability in raw fluorescence could be attributed to a multitude of factors. 
However, we suspect that the primary source of this variability is based on liquid delivery and handling, 
particularly of the fura-2 extraction buffer. Given that the readout of CFMEA is a fluorescent signal detected by 
a multimode detector, variation in fura-2 delivery could produce quantitative differences in detected 
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fluorescence. Although each experimental batch was prepared independently, the utilized fura-2 was from a 
single manufacturing lot, making differential fura-2 dye activity unlikely. Additionally, there is the possibility 
that variation in Mn exposure buffer delivery could have contributed to inter-plate differences in fluorescence 
intensity. However, the consistent pattern of intra-batch variation across the tested Mn concentrations makes 
variation in Mn exposure buffer delivery an unlikely culprit given that individual concentrations were composed 
and delivered independently. 
 
We have previously reported that transforming raw fura-2 fluorescence values into a percentage relative to 
vehicle could successfully account for signal differences both within and between batches (Kwakye et al. 2011). 
Based on this finding, we recommend standardizing all values during HTS to the average signal value across 
each plate. This quantitative method controls for inherent changes in signal across batches caused by changes in 
cellular growth or a given fura-2 aliquot. This standardization would not limit the ability to identify changes in 
fluorescence caused by the activity of small molecules within a small molecule library. Another advantage to 
this approach is that it eliminates the requirement of generating a standard curve for each batch, since the goal 
of HTS is to identify hits based on clear cut-offs in signal rather than quantitative differences among samples. 
Given the robustness of this method of analysis, CFMEA is well suited for applications detecting small 
differences ([Mn] ≥ 0.1µM) in cellular Mn status, with or without exogenous Mn exposure. The sensitivity of 
the assay permits detection of moderate changes in Mn status, a property of direct relevance in drug 
development for compounds of physiological relevance. 
 
Moving forward, we believe that CFMEA has to potential to be a valuable tool in the detection of cellular Mn 
levels in HTS protocols. We advise investigators seeking to utilize this method to employ a similar approach in 
validating the parameters (cell density, exposure paradigm, fura-2 concentration) for their cell-type of interest. 
Subsequently, determination of the Z-factor for the assay will be essential in determining eligibility for HTS 
robotic automation. Although we have discussed sources of variance in the context of this study, there are other 
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factors that may impact future applications of CFMEA for HTS, such as fura-2 manufacturing lot and storage 
conditions. Furthermore, investigators should be aware of the potential influence that experimental differences 
in fura-2 concentration, fluorometric plate reader sensitivity, and detection of Mn quenched fura-2 may have on 
variability in the context of CFMEA HTS (Kwakye et al. 2011). 
 
Thus, we have described an approach broadly applicable toward adapting toxicological assays for HTS: (1) 
determination of the optimal cellular density, exposure concentrations, and conditions targeting the most 
dynamic range of the standard curve, (2) adjustment of reagent concentration, extraction volume, and analysis 
method to minimize error, and (3) performance of a multiple batch assay to compute geometric variation, batch-
to-batch variability, and Z-factors. This multi-step process permits the rapid ascertainment of the suitability of a 
cellular-plate assay for HTS without significant investment of laboratory resources or utilization of automated 
robotic equipment. Should a given assay achieve Z-factors within the target range, further validations and pilot 
screens can be pursued with reasonable degree of certainty that HTS will be possible. As more toxicological 
assays are adapted for this purpose, we hope that drug development, toxicant characterization, and our 
understanding of underlying physiological responses will be improved significantly. 
 
Materials and Methods 
 
Cell Culture Supplies and Reagents 
 
Cell lines were grown in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum (Atlanta 
Biologicals, Lawrenceville, GA, and Sigma, St. Louis, MO), l-glutamine, 400 µg/ml G418 and Penicillin-
Streptomycin. Manganese (II) chloride heptahydrate (MnCl2·7H2O), was from Alfa Aesar (Ward Hill, MA). 
Ultra-pure fura-2 salt (cell-impermeable, ENZ-52007) was obtained from ENZO Biochem (New York, NY). 
The HEPES salt exposure buffer consisted of 25 mM HEPES buffer (pH 7.2), 140 mM NaCl, 5.4 mM KCl, and 
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5 mM d-glucose (Sigma). 1X ultra-pure phosphate-buffered saline (PBS), pH 7.4, without calcium and 
magnesium was used for post Mn exposure washes. Triton X-100 and sodium dodecyl sulfate (SDS) were 
obtained from Sigma. 
 
Cell Culture 
 
Murine striatal cell lines, wild-type STHdhQ7/Q7, were grown at 33°C using previously established protocols 
(Trettel et al. 2000, Kwakye et al. 2011, Kwakye et al. 2011). Of note, the striatum is amongst brain regions 
that accumulate the highest levels of Mn (Aschner et al. 2007, Aschner et al. 2009). These cells were plated in a 
96-well plate at varying cellular concentrations cells per 0.32 cm2 36 hours before Mn treatment and allowed to 
grow in a 33°C incubator. MnCl2 was added to HEPES salt exposure buffer the morning of exposure. Total 
extracted Mn levels were assessed by CFMEA. 
 
Cellular Fura-2 Manganese Extraction Assay (CFMEA) 
 
CFMEA was conducted by adapting a previously published protocol by our laboratory (Kwakye et al. 2011). 
Wild-type STHdhQ7/Q7 were cultured in 96-well tissue plates for 36 hours, media was removed, wells were 
washed once with 200µL PBS and exposed to 100µL of varying physiologically and/or toxicologically relevant 
MnCl2 concentrations (0µM, 25µM, 100µM, 500µM) (Aschner et al. 2007, Aschner et al. 2009, Bowman et al. 
2011). After exposure, the media was discarded and cells were washed three times with 200µL PBS. 
Subsequently, the cells were extracted at 33°C for three hours in the indicated volume of (75µL, 100µL, 125µL) 
0.1% Triton X-100 in PBS (PTx) with the indicated concentration of fura-2 (0.25µM, 0.5µM, 0.75µM). 
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Quantification of Extracted Manganese 
 
An in vitro non-cellular Mn standard curve was generated at 0.75µM fura-2 utilizing a sixteen point dataset 
with samples containing 1µL of different 100X stock Mn standards (0–100mM) added to 99µL of 0.5 µM fura-2 
in PTx and assayed in a 96-well plate (n=3). The average raw fluorescence signal values (RFU) of the 0µM Mn 
samples within each independent standard curve were defined as the 100% maximal fluorescence (mean 
fluorescencevehicle = 100%) for that experiment after background subtraction. Based on this value, a ratio relative 
to vehicle and expressed as a percentage (%Veh) was calculated for each sample (%Veh = 100 x (fluorescence-
sample/mean fluorescencevehicle)). These plotted values were then used to generate a cubic function using Prism 
(GraphPad) that related the concentration of Mn in nM (y) to %Veh at each concentration (y= -
11693*(%Veh)3+30939*(%Veh)2-28623*(%Veh)+9403.6), r2=0.9740. We then utilized this function to solve 
for the concentration of Mn extracted in experimental samples using Microsoft Excel.  
 
Statistical Analysis 
 
Calculations of subtracted background levels, %Veh, and solving for Mn concentration were performed in 
Microsoft Excel. Downstream analyses characterizing variability and calculation of standard deviation (SD) and 
normalized SD to allow comparisons of variance over different numerical scales are discussed in depth in the 
Discussion. Z-factor was calculated using the function below as originally described by Zhang et al. (Zhang et 
al. 1999). 
Z=1-(3*SDconcentration1+3*SDconcentration2)/|µconentration1 - µconcentration2|
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CHAPTER V 
 
CELLULAR MANGANESE CONTENT IS DEVELOPMENTALLY REGULATED IN HUMAN 
DOPAMINERGIC NEURONS3 
 
Abstract 
 
Manganese (Mn) is both an essential biological cofactor and neurotoxicant. Disruption of Mn biology in the 
basal ganglia has been implicated in the pathogenesis of neurodegenerative disorders, such as parkinsonism and 
Huntington’s disease. Handling of other essential metals (e.g. iron and zinc) occurs via complex intracellular 
signaling networks that link metal detection and transport systems. However, beyond several non-selective 
transporters, little is known about the intracellular processes regulating neuronal Mn homeostasis. We 
hypothesized that small molecules that modulate intracellular Mn could provide insight into cell-level Mn 
regulatory mechanisms. We performed a high throughput screen of 40,167 small molecules for modifiers of 
cellular Mn content in a mouse striatal neuron cell line. Following stringent validation assays and chemical 
informatics, we obtained a chemical ‘toolbox’ of 41 small molecules with diverse structure-activity 
relationships that can alter intracellular Mn levels under biologically relevant Mn exposures. We utilized this 
toolbox to test for differential regulation of Mn handling in human floor-plate lineage dopaminergic neurons, a 
lineage especially vulnerable to environmental Mn exposure. We report differential Mn accumulation between 
developmental stages and stage-specific differences in the Mn-altering activity of individual small molecules. 
This work demonstrates cell-level regulation of Mn content across neuronal differentiation. 
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
3 Adapted From: Kevin K. Kumar, Edward W. Lowe, Asad A. Aboud, M. Diana Neely, Rey Redha, Joshua A. 
Bauer, C. David Weaver, Jens Meiler, Michael Aschner, Aaron B. Bowman. 2014. Cellular manganese content 
is developmentally regulated in human dopaminergic neurons. Under review at Nature Scientific Reports. 	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Introduction 
 
Most essential metals are highly regulated throughout development, serving as required co-factors while also 
implicated in cytotoxic processes (Finney et al. 2003). Metal homeostasis is maintained through concerted 
mechanisms involving metal transporters, metallochaperone proteins, metal responsive signaling pathways and 
transcription factors, and sequestration of metals within sub-cellular organelles (Domaille et al. 2008). A 
complex regulatory biology is known to underlie the transport and handling of most essential metals including 
iron, copper, and zinc (Zecca et al. 2004, Cousins et al. 2006, Choi et al. 2009). However, little is known about 
intracellular handling of Mn, despite it being an essential cofactor of cellular processes that rely on Mn-
dependent enzymes such as superoxide dismutase (Mn-SOD), arginase, glutamine synthetase, and 
neurotransmitter synthetic enzymes (Aschner et al. 2007).  In excess, Mn is neurotoxic, producing a variety of 
motor and psychiatric disturbances that can be attributed to basal ganglia dysfunction (Bowler et al. 2003, 
Takeda 2003, Stredrick et al. 2004, Josephs et al. 2005) and an enhanced susceptibility to Mn exposure has 
been reported during fetal and infant development (Aschner et al. 2005, Erikson et al. 2007). Mn preferentially 
accumulates and elicits toxicity within basal ganglia structures such as the caudate, putamen, substantia nigra, 
and globus pallidus (Bowman et al. 2011). Specifically, Mn has been implicated in parkinsonism and 
Huntington’s disease, two neurodegenerative syndromes that show neuronal loss in the basal ganglia 
(Finkelstein et al. 2007, Lucchini et al. 2007, Williams et al. 2010, Gonzalez-Cuyar et al. 2013, Lechpammer et 
al. 2014). 
  
Mn transport into the central nervous system has been well characterized at the level of the blood-brain barrier 
(BBB), consisting of facilitated and active transport through divalent metal transporter 1 (DMT1), transferrin 
receptor (TfR), ZIP8 (Rabin et al. 1993, Erikson et al. 2002, Garrick et al. 2003), and other transporters. 
However, the role of these and other metal transporters in neuronal Mn transport is not well understood (Tuschl 
et al. 2013). Indeed, while a number of transporters (e.g. SLC30A10, ATP13A2, SPCA1 and SPCA2) 
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contribute to Mn detoxification, and other transporters have been identified as contributing to Mn uptake (e.g. 
DMT1, ZIP8 and ZIP14), none of these are selective to Mn and most have been studied only under extracellular 
Mn concentrations well above the levels of brain Mn (60µM–150µM) associated with neurotoxicity in vivo 
(Tuschl et al. 2013, Bowman et al. 2014). Mn-specific binding proteins or signaling pathways responsive to 
physiological Mn concentrations have not been described. 
 
Because optimal intracellular Mn concentrations likely change over developmental time and lineage, we 
postulated that neurons, and perhaps other cells, have cell-level homeostatic processes that regulate intracellular 
Mn content to cover cellular physiological demands while preventing cytotoxicity. Furthermore, utilization of 
distinct cellular Mn handling mechanisms may vary as physiological demand and availability of this co-factor 
change. Such regulatory processes may consist of similar mechanisms that have been identified for other 
essential metals (Zecca et al. 2004, Cousins et al. 2006, Choi et al. 2009), including: intracellular Mn sensors, 
Mn chaperones or storage proteins, and cell signaling systems with transcriptional and post-transcriptional 
control processes to regulate the balance of Mn across intracellular compartments. Identification of neuronal 
Mn handling processes has proven rather intractable by genetic and biochemical approaches, perhaps in part 
because phenotypes associated with insufficient or excess Mn are not clearly defined. We hypothesized that Mn 
handling mechanisms can be identified, and later studied, by using a novel chemical biology approach that 
relies on intracellular Mn levels as the outcome measure. To identify small molecules that modify cellular Mn 
content, we performed a high throughput screen for modifiers of intracellular Mn status under biologically 
relevant levels of Mn. We then utilized these small molecules to test the hypothesis that cellular mechanisms of 
Mn handling are developmentally regulated between the highly relevant human floor-plate lineage 
neuroprogenitors and their derivative mesencephalic dopaminergic neurons (Chun et al. 2001, Takeda 2003, 
Gitler et al. 2009). 
 
 
	  65 
Results 
 
High throughput screen identifies small molecules for manipulating neuronal Mn status 
 
Our laboratory had previously developed the Cellular Fura-2 Mn Extraction Assay (CFMEA) to enable rapid 
fluorescent-based measurements of intracellular Mn content (Kumar et al. 2013). Here, we utilized CFMEA for 
high throughput screening (HTS). The overall HTS approach consisted of pretreatment with the test small 
molecule, followed by co-exposure to 125µM MnCl2, representative of in vivo brain Mn levels at which aberrant 
function would be observed(Bowman et al. 2014). An immortalized murine striatal neuron lineage 
(STHdhQ7/Q7) was used the HTS, as the striatum, like other structures of the basal ganglia, has a relatively high 
basal Mn level and an especially high capacity for Mn accumulation (Kwakye et al. 2011, Kumar et al. 2013). 
After the Mn and small molecule incubation period, extracellular Mn was washed away and CFMEA performed 
(Figure 8A).  
 
	  66 
	  
Figure 8 – HTS identifies modulators of neuronal Mn status. (a) HTS screening protocol. Timeline of 
screening paradigm indicating cell plating, 10µM small molecule addition, Mn addition, washing, fura-2 
extraction, signal measurement, and analysis. (b) Composition of 40,167 screened small molecules. Individual 
small molecule libraries are labeled and total compounds in that collection are indicated. (c) HTS paradigm. 
Each stage of the screen and number of compounds refined at that stage. (d) Scatterplot of primary screen. Z-
score of each small molecule is indicated (n=1, per compound). A hit was defined as a small molecule with a z-
score or b-score (not shown) cutoff of ± 3.0 or larger, as indicated by dotted line (green). 
 
During optimization of the assay for 384-well format, we determined the major sources of intra-plate variability 
to be volumetric delivery of fura-2 extraction buffer. We developed a strategy to control for variability in 
delivered fura-2 by supplementing the fura-2 extraction buffer with a dextran-coupled fluorophore (Alexa-568) 
that does not interfere with fluorometric readings of fura-2. This enabled us to correct for variations in robotic 
volumetric delivery (achieving Z’>0.5) (Figure 9). These and other optimizations enabled detection of changes 
in fura-2 signal as low as 10%, corresponding to a z-score of ± 3.0. 
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Figure 9 – Checkerboard assay HTS-CFMEA pre- and post-assay optimization using Alexa-568 to 
control for variability in volumetric delivery. Percent fluorescence is plotted relative to vehicle exposure 
(%Veh) by plate position (384-well format). Concentration of Mn exposure indicated in legend: 31.25µM 
(green), 125µM (blue), 500µM (red). Z-factor calculated by Z=1-(3*SDconcentration1+3*SDconcentration2)/|µconentration1 
- µconcentration2|. Z’≥0.5, bidirectionally was observed after optimization of assay conditions by controlling for 
volumetric delivery variance. 	  
To comprehensively identify small molecules that modulate neuronal Mn levels, we screened a total of 40,167 
small molecules spanning multiple chemical libraries (Figure 8B). Of these, 901 (2.2% hit rate) small 
molecules increased or decreased Mn levels (z-score or b-score > ±3.0) (Figure 8C,D). These hits were first 
validated by replication in duplicate followed by generation of 1nM-10µM concentration response curves 
(CRCs). A total of 133 small molecules (0.33%) passed these criteria, displaying a variety of potencies and 
patterns of activity (Figure 10).  
	  
Figure 10 – Concentration response curves (CRCs) of primary screen hits. (A) Representative Mn 
decreasing small molecules CRCs plotted as percentage of maximum activity vs. log(concentration) of the 
indicated small molecule. (B) Representative Mn increasing small molecules CRCs with a less than two-fold 
effect size. (C) Representative Mn increasing small molecules CRCs with a greater than two-fold effect size. 
For all quantifications, data are mean ± SEM (n=2 per concentration). Convergence of curves was determined 
based on iteratively reweighted least squares analysis. 
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We then culled the toolbox of small molecules not readily obtainable from commercial or academic sources, 
leaving 65 for subsequent study. We further refined the toolbox by excluding fluorescent small molecules that 
could give false positive increases in fura-2 signal (Figure 11) and molecules that altered the number of cells 
under the conditions of the HTS screen due to cytotoxicity or other mechanisms (Figure 12).  
	  
Figure 11 – Native fluorescence of validate small molecules at fura-2 excitation/emission wavelength used 
in CFMEA. Data plotted as raw fluorescence for each small molecule ordered by mean raw fluorescence (n=3). 
Small molecule activity is indicated; Mn level increasing small molecules (in blue), and Mn level decreasing 
small molecules (in red). Horizontal lines indicate the detection limit of fura-2 fluorescence (green), and 
fluorophore cutoff (grey). Threshold for fluorescent properties was based on culling Mn level decreasing small 
molecules (which are detected by an increase in fluorescence signal relative to the no small molecule plus Mn 
control, thus fluorescence could lead to a false-positive detection) with a mean raw fluorescence greater than the 
vehicle (DMSO) + 6SD. This statistical cutoff corresponds to Z’=0 suggested for a yes/no determination assay. 
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Figure 12 – Toxicity of small molecules in the Mn toolbox. Toxicity of small molecules within Mn toolbox 
(blue) reported as percentage +/- of the positive control fluorescence in the vehicle treated cells (red) (n=4). 
None of the small molecules tested exhibited a statistically significant change in total viable cells, measured by 
one-way ANOVA relative to the DMSO vehicle control (green) (p<0.05). Two molecules, VU0482834 and 
VU0482794 were not available at time of toxicity testing. 
 
 
These validation and quality control measures resulted in a final Mn toolbox of 41 small molecules. The 
functional properties of this toolbox consisted of significantly more Mn level increasing small molecules than 
Mn level decreasing small molecules (Table 5) (Chi-square, p<0.05).  
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Table 5. Chemical structures of all 41 validated small molecules in the Mn toolbox. Data displayed include 
small molecule identity, chemical structures with IUPAC name, source small molecule library, direction of 
activity, and EC50 concentration. 
 
Small 
Molecule Structure Library 
Mn 
Activity logEC50 
VU0002852 
 
ChemBridge
/Div Increase -5.457 
VU0003610 
 
ChemBridge
/Div Increase -5.752 
VU0003765 
 
 
ChemBridge
/Div Increase -5.360 
VU0004838 
 
 
ChemBridge
/Div Increase -5.687 
VU0006021 
 
 
ChemBridge
/Div Increase -5.454 
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VU0006712 
 
ChemBridge
/Div Increase -6.385 
VU0009096 
 
 
ChemBridge
/Div Increase -6.377 
VU0009101 
 
 
ChemBridge
/Div Increase -6.412 
VU0009103 
 
 
ChemBridge
/Div Increase -6.294 
VU0025173 
 
ChemBridge
/Div Increase -6.834 
VU0025879 
 
 
ChemBridge
/Div Increase -5.416 
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VU0026395 
 
 
ChemBridge
/Div Increase -5.723 
VU0026921 
 
 
ChemBridge
/Div Increase -5.638 
VU0026977 
 
ChemBridge
/Div Increase -5.451 
VU0027832 
 
 
ChemBridge
/Div Increase -5.834 
VU0028040 
 
ChemBridge
/Div Increase -5.920 
VU0028386 
 
 
ChemBridge
/Div Increase -7.043 
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VU0029414 
 
 
ChemBridge
/Div Increase -5.927 
VU0029611 
 
 
ChemBridge
/Div Increase -5.078 
VU0035619 
 
ChemBridge
/Div Increase -6.338 
VU0041803 
 
ChemBridge
/Div Increase -5.706 
VU0046776 
 
ChemBridge
/Div Increase -5.629 
VU0047355 
 
 
ChemBridge
/Div Decrease -5.968 
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VU0047375 
 
 
ChemBridge
/Div Decrease -5.917 
VU0048129 
 
ChemBridge
/Div Decrease -5.899 
VU0050661 
 
ChemBridge
/Div Increase -6.677 
VU0057971 
 
ChemBridge
/Div Increase -6.286 
VU0063088 
 
ChemBridge
/Div Decrease -5.501 
VU0076546 
 
 
ChemBridge
/Div Increase -5.370 
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VU0088990 
 
 
ChemBridge
/Div Decrease -7.271 
VU0133141 
 
 
ChemBridge
/Div Increase -5.744 
VU0135086 
 
 
ChemBridge
/Div Increase -5.332 
VU0150155 
 
ChemBridge
/Div Increase -7.274 
VU0239513 
 
Spectrum 
Collection Increase -5.324 
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VU0243195 
 
 
Spectrum 
Collection Decrease -5.610 
VU0243305 
 
 
Spectrum 
Collection Increase -5.713 
VU0243403 
 
 
Spectrum 
Collection Increase -5.747 
VU0244366 
 
Spectrum 
Collection Decrease -5.808 
VU0482585 
 
GSK 
Published 
Kinase 
Inhibitor 
Set 
Increase -4.082 
VU0482794 
 
 
GSK 
Published 
Kinase 
Inhibitor 
Set 
Decrease -4.546 
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VU0482834 
 
 
GSK 
Published 
Kinase 
Inhibitor 
Set 
Decrease -8.634 
 
Given the tendency of small molecules from pharmacological screens to inhibit (antagonistic) rather than 
enhance (agonistic) the function of their biological target (Austen et al. 2005), this skewing toward Mn level 
increasing small molecules suggests Mn efflux mechanisms are more susceptible to pharmacological disruption 
than mechanisms of Mn influx. 
 
High structural diversity of validated small molecules 
 
We generated a heat map of pairwise Tanimoto coefficients (Figure 13), a measure of chemical structure 
similarity, using an upper triangle distance matrix considering largest common substructure between two 
molecules. As the majority of our identified small molecules have no known biological targets, we sought to 
reveal potential relationships between their chemical structure by performing hierarchical agglomerative 
clustering using complete linkage to generate functional dendrograms.  
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Figure 13 – Structure activity dendrogram and Tanimoto plot of Mn toolbox. Functional dendrogram with 
clustering based on chemical similarity as determined by Tanimoto score (1=identical, 0=unique). Small 
molecule activity pattern per node is indicated by color: Mn level decreasing small molecules (red), Mn level 
increasing small molecules (blue), and mixed activity (green). Compound Tanimoto scores for each small 
molecule were plotted across all compounds in the Mn toolbox represented by heat map. 
 
This analysis revealed a high degree of structural diversity, with an average pairwise Tanimoto coefficient of 
0.19, where a 1.0 translates to identical compounds and a 0.0 to compounds that have no common substructure. 
While three clusters of 2-4 similar molecules (Tanimoto coefficients >0.8) exist, most had little structural 
similarity with other active molecules (Tanimoto coefficient  <0.5) (Maggiora et al. 2014). This finding 
suggests that the screen did not identify the complete range of structure-activity relationships, likely reflecting 
both the diversity of biological targets that influence cellular Mn status, as well as the potential of diverse 
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structures to influence common targets.  The identified small molecule clusters all had Mn level increasing 
activity (Cluster 1 (VU0002852 and VU0003765), Cluster 2 (VU0088990, VU0029414), Cluster 3 
(VU0027832, VU0028040, VU0028386, VU0133141)).  
 
Activity of small molecules at normal brain Mn levels 
 
In the screen, small molecules were identified using a concentration of Mn associated with mammalian 
neurotoxicity in vivo (125µM). Subsequently, we sought to assess the Mn modifying activity of these small 
molecules under normal brain Mn levels. Although in vivo concentrations of Mn may not directly translate to in 
vitro exposures, it has been shown that normal levels of human brain Mn range from 20µM to 53µM (Bowman 
et al. 2014). Thus, we tested for activity at 31.25µM Mn, a four-fold dilution from the concentration used in the 
primary screen, that is also just above the minimum limit of Mn detection by CFMEA. The vast majority of 
small molecules (39/41, 95%) exhibited Mn-modifying activity at this Mn concentration (Figure 14).  
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Figure 14 – Activity of validated small molecules at physiological and toxicological Mn exposures. Fold 
change in Mn levels at both 31.25µM (blue) and 125µM (red) MnCl2 is plotted versus small molecule identity. 
Small molecules tested in hiPSC-derived mesencephalic floor plate neuroprogenitors and post-mitotic neurons 
are marked in (purple). ‘NS’ indicates small molecules that do not show significant activity for 31.25µM 
concentration. Horizontal lines indicate the detection limit of CFMEA (green), and no effect on Mn levels 
(grey). Data plotted as mean ± SEM (n=16 for 31.25µM, n=2 for 125µM). Statistical significance (all not 
marked by NS) was determined by comparing small molecule versus vehicle by one-way ANOVA, p<0.05. 
 
There was considerable variation in effect size between our high and low Mn exposure conditions, with some 
small molecules having greater activity (fold change of Mn) at 125µM Mn and others having greater activity at 
31.25µM Mn. Two molecules failed to have significant activity at 31.25µM (VU0243195 and VU0482834). 
One molecule, VU0076546, had a unique pattern of activity, increasing intracellular neuronal Mn levels at the 
high Mn concentration, but strongly decreasing intracellular Mn levels at the lower Mn concentration. 
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Chemical informatics reveals common pathways among predicted targets 
 
We performed a chemical informatics analysis of the 41 small molecule toolbox to identify potential biological 
targets. In order to reveal functional relationships between small molecules, we aggregated information 
regarding known targets of each molecule and its similar chemical homologs (Tanimoto coefficient >0.7). The 
structures of the entire Mn toolbox were inputted into STITCH 4.0 analysis generating two major signaling 
node clusters, with only 5 of the 41 chemicals having structural homologs with known or suspected biological 
activity. VU0482585, VU0239513, VU0482834, and VU0243195 exhibited multi-nodal interactions with a 
network comprised of mitogen-activated protein kinase 14 (MAPK14), transforming growth factor beta receptor 
I (TGFBR1), glutathione S-transferase P (GSTP1), superoxide dismutase 1 (SOD1), copper-transporting 
ATPase 1 (ATP7A), ATP-binding cassette sub-family C member 2 (ABCC2), and ATP-binding cassette sub-
family G member 2 (ABCG2) (Figure 15A). These predicted interactions were further supported by the fact 
that VU0482585 and VU0482834 were from the GSK Published Kinase Inhibitor Set (Drewry et al. 2014), 
suggesting a mechanism related to kinase inhibition or disruption of ATP-dependent transporters. In addition, 
homologs of VU0003610 have known binding to butyrylcholinesterase (BCHE) and acetylcholinesterase 
(ACHE) (Figure 15B). 
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Figure 15 – Chemical informatics analysis of Mn toolbox. (A,B) STITCH analysis of Mn toolbox small 
molecules. Each node represents a small molecule or target protein. Color coded asterisk indicates 
corresponding small molecule or small molecule homolog (Tanimoto score > 0.7) validated in the HTS, 
identified in the legend. Color of connections between nodes indicates known function and description of the 
type of evidence available: activation (green), inhibition (red), binding (blue), catalysis (purple), and 
expression (yellow). 
 
While these findings provide some insight into potential biological targets, the majority of our identified small 
molecules, and their close chemical homologs, do not have other published biological activities. This suggests 
that the neuronal Mn status modifying activity of our validated small molecules is relatively specific since such 
structures have not been identified in other published screens performed on the same publically available 
chemical libraries. 
 
Differential regulation of Mn handling in developing mesencephalic dopaminergic neurons 
 
We hypothesized that small molecules in our Mn-modifying chemical toolbox would exhibit differential 
activity across neurodevelopmental time as the biological requirements for Mn change. We tested this 
hypothesis in developing human mesencephalic (floor plate lineage) dopaminergic neurons, given this lineage’s 
particular susceptibility to Mn toxicity and involvement in neurodegenerative syndromes such as parkinsonism 
(Chun et al. 2001, Takeda 2003, Gitler et al. 2009). Human induced pluripotent stem cells (hiPSCs) generated 
from a control subject were differentiated into FOXA2+, LMX1A+ floor-plate lineage neuroprogenitors (12 
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days differentiation) and further to Tyrosine hydroxylase (TH)+, β3-Tubulin+, LMX1A+ post-mitotic early 
dopaminergic neurons (26 days differentiation) (Figure 16A). Mn handling was quantified by CFMEA 
following 125µM MnCl2 exposure (Okita et al. 2008, Kriks et al. 2011). Early dopaminergic neurons (day 26) 
accumulated significantly (p<0.05) more intracellular Mn than the more immature floor plate neuroprogenitors 
(day 12) (Figure 16B). 
 
	  
Figure 16 – Mn accumulation changes across developmental time in mesencephalic floor-plate 
neuroprogenitors and/or post-mitotic dopaminergic neurons. (a) Immunocytochemistry of day 12 floor 
plate neuroprogenitors and day 26 post-mitotic dopaminergic neurons. Appropriate developmental stage 
markers indicated by legend. (b) Mn accumulation in day 12 and day 26 neuroprogenitors after Mn exposure 
(125µM). Data is expressed as Mn/DNA (nmol/µg) versus developmental time point. Data are mean ± SEM 
(n=3). Statistical significance by one-way ANOVA (*p<0.05). 
 
 
Nine small molecules of varying structures and effect sizes were selected to evaluate their activity in this human 
system and test for potential developmental stage specificity. All tested small molecules (9 of 9) showed 
activity in hiPSC-derived mesencephalic dopaminergic neuroprogenitors (one-way ANOVA, p<0.001). Three 
of the small molecules (3 of 9, 33%) showed similar magnitude of activity at both neurodevelopmental time 
points (Figure 17A-C).  Four of the small molecules (4 of 9, 44%) exhibited greater activity in floor plate 
neuroprogenitors than post-mitotic dopaminergic neurons (Figure 17D-G).  Finally, two small molecules 
showed developmental-stage specific activity (2 of 9, 22%) (Figure 17H,I). VU0047355, a negative modulator 
of Mn concentration, and VU0482585, a positive modulator of Mn concentration, exhibited a significant impact 
a
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on intracellular Mn levels exclusively in the more mature dopaminergic neurons, the developmental time point 
with the highest Mn accumulation between the two stages of differentiation (Figure 17H,I). These results 
demonstrate that the validated small molecules act on developmentally regulated targets involved in control of 
intracellular neuronal Mn handling. 
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Figure 17 – Mn toolbox is effective in hiPSC-derived mesencephalic floor-plate neuroprogenitors and/or 
post-mitotic dopaminergic neurons. (A-I) Activity of selected small molecules at indicated 
neurodevelopmental stage. Data is expressed as fold change in Mn level of small molecule versus vehicle at 
indicated developmental time point. Data are mean ± SEM (n=3). Statistical significance by one-way ANOVA 
(small molecule versus vehicle) is indicated by white asterisks within the colored bars of the graph, and 
significance by unpaired t-test (day 12 versus day 26) is indicated by asterisks above the brackets between the 
compared bars; (*p<0.05, **p<0.001). 
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Discussion 
 
HTS technology permits the rapid testing of thousands of small molecules for their impact on a particular 
biological system (Inglese et al. 2007, Macarron et al. 2011). Our application of HTS is distinct from the more 
typical HTS approaches targeting specific proteins or enzymatic processes. Our approach would thus be 
expected to lead to a larger number of potential biological targets, increasing the probability of finding true hits 
over traditional screens with only one or a few targets. The CFMEA high throughput screen identified a 
chemically diverse toolbox of 41 small molecules that increase or decrease intracellular Mn levels. Despite 
testing 40,167 small molecules, only a few chemical structural similarity clusters were identified, suggesting we 
likely did not identify the complete range of structure-activity relationships that influence cellular Mn status. 
The vast majority (39/41) of small molecules in the Mn toolbox retained activity at low Mn concentrations, 
representative of normal brain Mn levels (Bowman et al. 2014). This conservation of activity at healthy Mn 
levels suggests that the majority of our small molecules target homeostatic processes mediating normal neuronal 
Mn content, rather than those functioning only under toxicological concentrations. 
 
We have examined potential structure-function relationships by employing a chemical informatics approach to 
characterize the validated small molecules. Information was found regarding functional targets for five of the 41 
small molecules, implicating a major signaling pathway with known links to Mn biology. For example, 
MAPK14 (p38-α) has been shown to activate in cells responding to cytotoxic levels of Mn, 250µM Mn or 
higher (Hirata et al. 2004, Bae et al. 2006). Excessive Mn can increase oxidative stress, COX-2 expression, and 
glutathione depletion (Zhang et al. 2007). VU0482585, identified by STITCH analysis (Figure 15A) as a 
potential inhibitor of the MAPK14, has confirmed Mn level increasing activity in post-mitotic human 
dopaminergic neurons (Figure 15B). Together, these data suggest a potential link between the MAPK14 
signaling pathway and control of neuronal Mn content under conditions of excess Mn. The identification of 
ABCC2 and ABCG2 as putative targets is also noteworthy given their role in unidirectional efflux of toxic 
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substances and known expression in stem cell like populations (Patrawala et al. 2005, Nies et al. 2007). Aside 
from these putative signaling protein targets, our chemical structure associations implicated interactions with 
enzymes involved in neurotransmission, ACHE and BCHE, consistent with cholinergic disruption occurring 
with Mn exposure (Finkelstein et al. 2007, Santos et al. 2012). These and other functional leads suggest our 
chemical toolbox has high utility for future studies aimed at identifying mechanisms underlying Mn 
neurobiology.  
 
We tested the hypothesis that mechanisms regulating intracellular Mn content are developmentally regulated in 
differentiating dopaminergic neurons, given their known susceptibility to Mn toxicity in the context of 
parkinsonism (Olanow 2004, Kumar et al. 2012). This work provides compelling evidence for the 
developmental regulation of cellular Mn content, as six of the nine small molecules tested showed significant 
differences in activity between post-mitotic dopamine neurons and floor plate lineage neuroprogenitors (Fig. 
17D-I). Furthermore, our data demonstrate the existence of cellular-based Mn handling processes, as 
pharmacological modes of action acting directly on the Mn ion (e.g. as an ionophore or metal chelator) would 
not be expected to display developmental stage specific activity. High evolutionary conservation of Mn 
handling targets is also strongly suggested by the fact that 9 of 9 tested small molecules identified via a mouse 
neuronal model showed activity in a human neuronal model system. The fact that the small molecules identified 
with stage-specific activity included both Mn level increasing and Mn level decreasing small molecules 
suggests that processes capable of responding to both insufficient and excess Mn are utilized to achieve optimal 
cellular Mn content. 
 
In summary, we utilized a chemical biology approach to develop a highly diverse small molecule toolbox of 
neuronal Mn content modifiers. This Mn toolbox is comprised of small molecules capable of modulating 
intracellular Mn levels under both physiological and toxicological conditions. Biochemical informatics analysis 
has implicated modulation of cellular signaling pathways with intriguing links to Mn biology and human 
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disease. The identified small molecules exhibit activity in a clinically relevant human dopaminergic neuronal 
lineage. Furthermore, we report strong evidence for the regulation of intracellular Mn levels over human 
neurodevelopment. The collection of small molecules described here is the most complete, publically available, 
resource for interrogation of Mn handling processes and provides a template for development of therapeutic 
agents for neurological disorders associated with disruption of Mn homeostasis. 
 
Materials and Methods 
 
High throughput screening 
 
CFMEA was optimized for HTS to detect both Mn level increasing and decreasing small molecules of neuronal 
Mn status in mammalian cells. Checkerboard assays, using either 500µM or 31.25µM MnCl2 as a positive 
control relative to the 125µM MnCl2 used as the baseline Mn exposure condition, confirmed Z’>0.5 in both 
directions (Zhang et al. 1999) and enabling a robust screen in 384-well format (Figure 9). Quality controls were 
included on each plate for normalization on a plate-by-plate basis. Wild-type StHdhQ7/Q7 immortalized murine 
striatal cells were plated at a density of 3,000 cells per 384-well 16 hours prior to assay start time. Media was 
removed and the cells washed by ELX405 Microplate Washer (Bio-Tek) with 1X Hank’s-Balanced Salt 
Solution (HBSS) with calcium and magnesium (Corning) prior to application of 20µL of 1.5X (15µM) small 
molecule in HBSS. Plates were incubated for 30 minutes at 37°C, and 10µL of 3X (375µM) MnCl2 in HBSS 
was applied leading to a final concentration of 125µM MnCl2 and a nominal concentration of 10µM for the 
small molecule to be tested. Liquid deliveries were made using a Velocity 11 Bravo liquid handler (Agilent). 
Plates were incubated for 3 hours at 37°C. Incubation was terminated by a five cycle wash and plate blotting to 
remove any residual volume. CFMEA was performed by adding 30µL fura-2 extraction buffer (0.1% Triton-
X100, 0.5µM fura-2 ultra pure (Enzo Life Sciences), 100µM Dextran Alexa-Fluor 568 (Life Technologies) was 
loaded by Multidrop Combi Reagent Dispenser (Thermo Scientific). Plates were then incubated for two hours at 
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37°C and read using FITC filters, 350/25nm (excitation) and 525/25nm (emission) for fura-2, and 545/25nm 
(excitation) and 620/30nm (emission) for Alexa 568, by EnVision Multilabel Reader (Perkin Elmer). Data was 
analyzed with Pipeline Pilot (Acellrys) and Microsoft Excel. Hits were identified in the single point primary 
screen by z-score and b-score approaches (Brideau et al. 2003), then confirmed by duplicate experimental 
replicates. CRCs were generated by iteratively reweighted least squares, allowing determination of convergence 
and EC50 (Street et al. 1988, Rousseeuw et al. 2002). Native fluorescence of small molecules was assessed by 
measurement of 0.5µM of the test small molecule (or 0.5µM fura-2 as a positive control) at the same excitation 
and emission wavelengths used for CFMEA. Fluorescence of each small molecule was compared to +6 S.D. 
above the DMSO negative control. Cytotoxicity was evaluated by CellTox Green cytotoxicity assay (Promega) 
under identical conditions as the HTS paradigm. After this period, the CellTox Green dye was added and signal 
was measured using, monochromatic wavelengths 500nm (excitation) and 523nm (emission) using EnSpire 
Multimode Plate Reader (Perkin Elmer). Toxicity determination included lysed cells as a positive control. Small 
molecule libraries included collections from NIH Clinical Collection I/II, Microsource Spectrum Collection, 
kinase inhibitors from GlaxoSmithKline, Enzo Life Sciences, and Roche, Vanderbilt non-steroidal anti-
inflammatory library (NSAIDs), Vanderbilt bioactive lipid library, ChemBridge, and ChemDiv. 
 
Chemical similarity analysis 
 
Similarity analysis using the BCL::CHEMINFO Suite was performed on the 41 validated small molecules 
(Butkiewicz et al. 2013). Three dimensional representations of the molecules were generated using Corina 
(Sadowski et al. 1993). An upper triangle distance matrix considering largest common substructure between 
two molecules, (A⋂B)/(A⋃B), was generated using a common subgraph isomorphism algorithm. The vertices 
and edges were colored by atom type and bond type, respectively. BCL::CLUSTER was used to perform 
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hierarchical agglomerative clustering using complete linkage to generate color-coded dendrograms to visualize 
structural similarity and activity simultaneously (Alexander et al. 2011).  
 
hiPSC neuroprogenitors 
 
A hiPSC line generated from a control subject (CC3), using established methods in our laboratory following the 
work of Dr. Shinya Yamanaka (Okita et al. 2008, Neely et al. 2012), was utilized for all human studies. 
Pluripotency was validated by Pluritest (Muller et al. 2011), euploid karyotype was confirmed (Genetic 
Associates, Nashville TN), and the absence of the reprogramming plasmid integration was confirmed by PCR. 
 
Mn quantification in human floor-plate lineage dopaminergic neurons 
 
Dopaminergic differentiation of hiPSCs was performed exactly as described (Kriks et al. 2011), except 
LDN193189 (Stemgent) was used at 400 nM. To assess Mn levels on day 12 of differentiation (floor-plate 
lineage neuroprogenitors) and day 26 of differentiation (post-mitotic dopaminergic neurons) of differentiation, 
cells were dissociated with Accutase (Stem Cell Technologies) on day 10 or 24 and replated at a density of 
50,000 cells/well onto Matrigel-coated 96-well plates containing: 100% N2 medium with ROCK-inhibitor (10 
µM, StemCell Technologies) for day 10 cells and Neurobasal medium (Invitrogen) supplemented with 
B27/glutamax, CHIR (3µM, Stemgent), brain-derived neurotrophic factor (BDNF) (R&D, 20ng/mL), glial cell 
line-derived neurotrophic factor (GDNF) (R&D, 20ng/mL), ascorbic acid (Sigma, 200mM), TGFβ3 (R&D, 
1ng/mL), DAPT (Tocris, 10µM), and dibutyryl cAMP (Sigma, 0.5mM) containing ROCK-inhibitor (10 µM) for 
day 24 cells. On day 11 and 25 of differentiation, cells were fed with the aforementioned media without ROCK-
inhibitor. Net Mn uptake via the same paradigm utilized in the murine striatal cells (30 minutes pre-incubation 
with vehicle or small molecule at 15µM, followed by 3 hours 125µM MnCl2 in HBSS with continued presence 
of vehicle or small molecule at 10µM) was assessed the following day by CFMEA. 
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Immunofluorescence 
 
Immunocytochemistry of human neural lineages was performed as described(Neely et al. 2012), with the 
following antibodies: FOXA2 (1:100, BD Biosciences), LMX1A (1:1000, Millipore), β-III tubulin (TU-20) 
(1:500, Thermo Scientific), and TH (Pel-Freez, 1:500). 
 
STITCH analysis 
 
Protein chemical interactions were predicted with STITCH 4.0 (Kuhn et al. 2014). SMILE strings were 
exported from all validated small molecules with known functional targets. Analysis included structures with 
Tanimoto scores greater than 0.7. Action view diagrams were generated to illustrate known protein-chemical 
relationships of all connected nodes.
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CHAPTER VI 
 
UNTARGETED METABOLOMICS IN HUNTINGTON’S DISEASE STRIATAL CELL MODEL 
SHOWS DISEASE-DEPENDENT AND DISEASE-MANGANESE INTERACTIONS IN METABOLIC 
PATHWAYS 4 
 
Abstract 
 
Manganese (Mn) is an essential micronutrient for development and function of the nervous system. Deficiencies 
in Mn transport have been implicated in the pathogenesis of Huntington’s disease (HD), an autosomal dominant 
neurodegenerative disorder characterized by loss of striatal medium spiny neurons. Brain Mn levels are highest 
in striatum and other basal ganglia structures, and are also the most sensitive brain regions to Mn neurotoxicity.  
Murine models of HD exhibit decreased striatal Mn accumulation and HD striatal neuron models are resistant to 
Mn cytotoxicity. To better understand the physiological basis of this disease-toxicant interaction we sought to 
define cellular metabolic phenotypes influenced by Mn exposure and/or the pathogenic HD genotype. Here we 
use an unbiased metabolomics approach by performing ultra-performance liquid chromatography-ion mobility-
mass spectrometry (UPLC-IM-MS) on control and HD immortalized murine striatal neurons to identify 
metabolic disruptions under three Mn exposure conditions, low (vehicle), moderate (non-cytotoxic), and high 
(cytotoxic). Our analysis revealed lower metabolite levels of pantothenic acid, and glutathione (GSH) in HD 
striatal cells. HD striatal cells also exhibited lower abundance and impaired induction of isobutyryl carnitine in 
response to increasing Mn exposure. In addition, we observed induction of metabolites in the pentose shunt 
pathway in HD striatal cells after exposure to the highest concentration of Mn. These findings provide 
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Untargeted metabolomics reveals Huntington’s disease striatal neurons demonstrate altered basal metabolism 
and response to manganese exposure. In Preparation. 	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metabolic evidence of an interaction between the HD genotype and environmentally relevant Mn exposures in a 
striatal neural lineage. The metabolic phenotypes detected support existing hypotheses that changes in energetic 
processes underlie the pathobiology of both HD and Mn neurotoxicity.  
 
Introduction 
 
HD is a highly debilitating, autosomal-dominant neurodegenerative disorder characterized by motor 
dysfunction, behavioral abnormalities, and cognitive decline (Walker 2007). In HD, an expanded CAG repeat 
generates a pathogenic polyglutamine tract near the N-terminus of Huntingtin (HTT). Expansion of this 
polyglutamine tract is hypothesized to confer a toxic gain of function to HTT (Giorgini 2013). Furthermore, 
though HTT is universally expressed, HD is characterized by selective neuropathological changes including 
atrophy of the caudate and putamen with prominent vulnerability of the striatal medium spiny neurons (MSNs) 
(Vonsattel et al. 1998). 
 
Although mechanisms of neurodegeneration in HD are still under investigation, several classes of neuronal 
stress have been implicated in its pathogenesis, including oxidative stress, mitochondrial dysfunction, glutamine 
sensitivity, and metabolic dysregulation (Lin et al. 2006). Congruently, many environmental toxicants are also 
known to elicit similar types of neuronal stress, such as the pro-oxidant metal manganese (Mn), which causes 
striatal neurotoxicity in excess (Brouillet et al. 1993, Liu et al. 2006). MSNs in the striatum exhibit disruptions 
in neurochemistry and morphology in the context of Mn exposure (Madison et al. 2012). HD genotype prevents 
characteristic increases in MSN total dendritic length and branching found from week 13-16 in murine 
development and decreases in total spine density at week 16 (Madison et al. 2012). These pathophysiological 
changes in MSNs coincide with the onset of hyperkinetic behavioral abnormalities observed in murine models 
of HD (Slow et al. 2003). While the mechanism underlying disruptions in synaptic morphology resulting in 
behavioral phenotypes is poorly understood, it has been proposed that downstream alterations in neuron 
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connectivity and excitability, impact signal propagation for higher functions (Jaslove 1992, Mainen et al. 1996, 
Woolley et al. 1997, Tsay et al. 2004, Schmidt-Hieber et al. 2007). Interestingly, murine models of HD also 
exhibit disruptions in dopaminergic signaling (Cha et al. 1998, Bibb et al. 2000, Ortiz et al. 2011) and levels of 
striatal dopamine (Tang et al. 2007). Neurotoxic exposures to Mn have been shown to produce a similar 
depletion in striatal dopamine levels as is seen in HD (Madison et al. 2012). Notably, Mn exposure has been 
associated with changes in energy metabolism (Levin et al. 2005, Guilarte 2010). Furthermore, both in vitro and 
in vivo murine models expressing mutant HTT exhibit reduced total Mn accumulation (Williams et al. 2010). 
Despite the specificity of this HD-Mn interaction effect, the mechanisms by which pathogenic alleles of HTT 
disrupt Mn transport are unknown, though it appears to be independent of the HD iron transport phenotype. We 
hypothesize that the influence of mutant HTT on Mn cellular transport processes are a consequence of 
compensatory metabolic responses to HD pathophysiological processes. 
 
Here we interrogate intracellular metabolite profiles from a control and HD striatal cell model, mutant 
STHdh[Q111/Q111] and wild type STHdh[Q7/Q7]), demonstrated to exhibit a strong HD-Mn interaction 
phenotype under three extracellular Mn exposure conditions (Figure 18) (Williams et al. 2010, Williams et al. 
2010). Given that normal levels of brain Mn in mammals range from 20-53µM, we sought to assess the ability 
of Mn to influence the metabolic profile at low (0µM), moderate non-toxic (31µM), and high toxicological 
exposure concentrations (125µM) (Bowman et al. 2014). An unbiased assessment of intracellular metabolic 
perturbations was performed through a comprehensive small molecule profiling approach using ultra-
performance liquid chromatography-ion mobility-mass spectrometry (UPLC-IM-MS) (Derewacz et al. 2013). 
This approach enabled study of HD-Mn interactions at a cellular level without a priori knowledge of HD or Mn 
induced protein changes. Sampling the metabolite inventories of cells provides information representative of the 
striatal cell phenotype, and is reflective of the current biology of the system. The metabolomic profiling method 
has the potential to reveal mechanistic and therapeutic targets that may not be captured by genetic and 
transcriptional approaches. Here we describe the first application of unbiased metabolomics to study gene-
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environment interactions in a neurodegenerative disorder. Our study provides an integrated overview of the 
effects of genotype, Mn exposure, and HD-Mn interactions on metabolic pathways via quantifying their 
respective metabolites independent of any prior association with HD pathogenesis or Mn biology. Specifically, 
we investigated the metabolomic profiles of mutant (STHdhQ111/Q111) and wild type (STHdhQ7/Q7) immortalized 
striatal neuroprogenitors in response to increasing concentrations of extracellular Mn (Trettel et al. 2000). Both 
basal metabolic differences in HD versus wild type striatal cells were observed, as well as the Mn-dependent 
and HD by Mn interaction dependent responses in metabolite composition were identified.  
 
 
Figure 18 – Study of HD-Mn interaction using untargeted metabolomics. Overall paradigm for 
experimental approach. Murine control (STHdhQ7/Q7) and HD (STHdhQ111/Q111) striatal cell model were treated 
by different Mn exposure conditions. Cells were harvested for metabolomics profiling and identification 
followed by pathway correlation. 
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Results 
 
Both HD genotype and manganese concentration affect metabolomic profiles of neurons 
 
In all, 475 features were detected with unique retention time and m/z values. We performed ANOVA across all 
samples, grouping technical replicates, and removing all values with a p-value greater than 0.10. This resulted 
in 362 filtered features used for all subsequent analyses. Our data suggest deviations in the metabolomic 
profiles of both control and HD striatal cell lines are driven primarily by the concentration of manganese to 
which they are exposed. We sought to assess the ability of Mn to influence the metabolic profile both at a 
physiological Mn concentration (31.25µM) and at an in vivo relevant toxicological concentration (125µM) 
(Bowman et al. 2014). Principle component analysis (PCA) shows separation of global metabolomic profiles in 
principal component one (PC1) based upon treatment conditions (Figure 19). Each marker represents the 
average metabolomic profile of one biological sample analyzed in triplicate and ANOVA filtered. Biological 
replicates cluster in PCA space, indicating biological consistency of these measurements. However, PC2 
separates metabolomic profiles predominantly based upon cell genotype, suggesting differences in basal 
metabolism between the metabolomic profiles of STHdh[Q7/Q7] and STHdh[Q111/Q111] cells. Self-organized 
heat maps (Figure 19) that cluster metabolites by covariance were then used to visualize global patterns of 
metabolite changes between control and HD striatal cells with varying Mn exposures (Eichler et al. 2003, 
Goodwin et al. 2014). In this method, metabolites self-assemble into groups in a user-defined grid based upon 
similarities in abundance profiles using an unsupervised computational process. For example, metabolites that 
are increased in abundance consistently across biological replicates as a generic response to Mn concentration 
will be grouped in a region of the SOM space, while metabolites that are produced as a genotype-specific 
response to Mn concentration will group in a separate, distinct region of SOM space. Experimental groups are 
then represented as heat maps based upon the abundances of organized metabolites. The number of metabolites 
seeded in each grid location of the SOM in Figure 19B is indicated in the metabolite density map, with blue 
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representing one metabolite and red corresponding to 44 metabolites. The largest abundance occupying the 
central region of the SOM space corresponded to a large peptide with a molecular weight of 8561.6 Da, 
putatively identified as ubiquitin based upon accurate mass (Table 6). Through SOM analysis, we observed a 
decreased production of glutathione (GSH) and pantothenic acid in the STHdh[Q111/Q111] cell line. A general 
linear model was applied to evaluate significant differences in the abundance of metabolites by genotype, Mn 
exposure, or genotype by Mn exposure interaction. A significant relationship between genotype and both GSH 
and pantothenic acid abundance was observed (p<0.001). Both genotype (p<0.05) and Mn exposure (p<0.005) 
had a significant effect on the levels of isobutyrl carnitine. There was also a statistically significant interaction 
between genotype and Mn-exposure on isobutyryl carnitine abundance (p<0.05). Finally, ribulose-5-phosphate, 
showed a significant change in abundance by Mn exposure (p <0.001), genotype (p<0.001), and a genotype by 
Mn exposure interaction effect (p<0.01). 
  
Table 6. Measured accurate masses for metabolite identifications. 
 
Metabolite Measured Mass Mass Accuracy (ppm) 
Isobutyryl carnitine 232.153 6.0 
Ribulose 5-phosphate 231.0254 4.3 
Glutathione 308.0926 4.9 
Pantothenic acid 220.1192 5.9 
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Figure 19 – Untargeted metabolomics reveals metabolites impacted by Mn and/or HD genotype. (A) 
Principal component analysis of metabolomic profiles for STHdh[Q7/Q7] and STHdh[Q111/Q111] cells 
exposed to varying physiologically-relevant Mn concentrations. (B) Self-organized metabolic heat maps with 
select metabolites annotated. (C-G) Box plot production profiles for significant metabolites. (STHdh[Q7/Q7] 
represented by gray bar, STHdh[Q111/Q111] represented by white, manganese concentration on abscissa, 
standard error about the mean is shown). 
 
 
Discussion 
The application of untargeted metabolomic profiling to characterize Mn-dependent cellular responses in an HD 
striatal cell model has revealed several alterations in metabolism based on genotype and Mn-exposure 
conditions and HD x Mn interaction effects. These findings have the potential to directly link established 
differences in cellular Mn handling in HD with neuronal responses to Mn burden. 
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HD striatal cells exhibit lower levels of pantothenic acid and GSH 
 
The identification of lower levels of pantothenic acid (vitamin B5) and GSH in HD striatal cells fits into the 
complex biology mediating neuronal mitochondrial processes and metal handling. Notably, disruptions in 
pantothenic acid levels have been described in a related neurodegenerative disorder, brain iron accumulation 
(NBIA), also known as Hallervorden-Spatz disease (Swaiman 1991, Kotzbauer et al. 2005). Mutations in 
pantothenate kinase 2 (PANK2), encoding a neuronal mitochondrial protein responsible for catalyzing the 
phosphorylation of pantothenic acid to phosphopantothenate, have been identified in one-third of patients with 
this disorder (Begley et al. 2001, Hayflick et al. 2003). This process is critical to the synthesis of coenzyme 
(CoA), a universal acyl carrier involved in the citric acid cycle and cellular energetics. In addition, pantothenic 
acid is a necessary co-enzyme for the synthesis of GSH, and has been shown to protect cells from peroxidative 
damage by increasing free GSH levels (Slyshenkov et al. 2004). Given our observation of decreased 
pantothenic acid levels relative to control, downstream impaired cellular energetics and exhausted response to 
oxidative stress could play a role in neurodegeneration observed in HD. Mn neurotoxicity can result from 
enhanced production of free radicals that are scavenged by GSH and other antioxidants (Vescovi et al. 1989). 
However, the decreased abundance of GSH and pantothenic acid we observed appear to be independent of 
cellular Mn burden given the lack of Mn-dependent changes. Importantly, it remains possible that the HD 
genotype dependent changes in GSH and pantothenic acid may be acting upstream of the changes in Mn 
cellular biology.  
 
Alterations in levels of ribulose-5 phosphate implicate modulation of the pentose shunt pathway in HD 
 
The pentose shunt pathway functions to regenerate the reducing agent NADPH, which is necessary for the 
many biosynthetic processes in the brain, such as synthesis of free fatty acids from acetyl-CoA (Magistretti et 
al. 2013). The dehydrogenation of glucose 6-phosphate to ribulose 5-phosphate is the rate-limiting step of the 
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pentose shunt pathway. The pentose shunt pathway is induced by p53, a protein known to mediate cellular 
dysfunction and behavioral abnormalities in HD (Bae et al. 2005). Our data suggest increasing cellular Mn 
burden results in a corresponding induction of ribulose 5-phosphate, an effect that was exaggerated in HD 
striatal cells relative to control. This finding corroborates previous studies that demonstrate HD striatal cell 
impairments in mitochondrial dynamics and energetics (Jin et al. 2011, Jin et al. 2012). The genotype-
dependent difference was apparent only at the cytotoxic 125µM Mn exposure, while changes in cellular Mn 
burden going from vehicle to 31µM does not significantly increase ribulose 5-phosphate levels. This is 
consistent with an involvement of ribulose 5-phosphate metabolism in the Mn cytotoxic cellular response. 
Indeed, NADPH generated in production of ribulose 5-phosphate mediates the generation of GSH by reducing 
glutathione disulfide (GSSG). Increased ribulose 5-phosphate levels suggest that HD striatal cells are 
hypersensitive to Mn related oxidative stress, despite their reduced net Mn accumulation. Furthermore, when 
taken into the context of decreased levels of glutathione and pantothenic acid in HD striatal cells, increased 
levels of ribulose 5-phosphate may be a cellular response to increase the reduced amount of GSH available for 
handling oxidative stress. 
 
HD striatal cells exhibit lower abundance and an impaired Mn-dependent increase of isobutyryl carnitine 
 
Isobutyryl carnitine is a product of the acyl-CoA dehydrogenases, mitochondrial enzymes that are involved in 
the process of metabolism of fatty acids or branched-chain amino acids. In addition to these functions, 
carnitines have well described roles in the brain including: lipid synthesis, membrane composition, expression 
modulation, mitochondrial energetics, activation of antioxidant mechanisms, and strengthening cholinergic 
neurotransmission (Jones et al. 2010). Although, increases in isobutyryl carnitine levels have been observed in 
inborn errors of metabolism such as short chain acyl dehydrogenase deficiency, reduced levels of this 
metabolite have not been reported in the context of any neurodegenerative disease (Dwight et al. 2003). Our 
data reveal genotype, Mn exposure and genotype by Mn interaction effects for levels of isobutyryl carnitine. We 
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observed that Mn exposure induces elevated levels of isobutyryl carnitine in control striatal cells but not the HD 
mutant cells. As HD striatal cells accumulate significantly less cellular Mn levels versus control cells (Williams 
et al. 2010, Williams et al. 2010), the genotype specific effect is likely due to a failure to reach a sufficient 
threshold level of intracellular Mn. The observation that levels of isobutyryl carnitine increased in control 
striatal cells only at the highest Mn exposure is consistent with this interpretation. Mn toxicity occurs in part via 
impairment of mitochondrial function (Claudia et al. 2004, Dobson et al. 2004). The increase in this metabolite 
under conditions of heavy Mn burden may reflect increased reliance on isobutyrl carninite-mediated process to 
generate acetyl-CoA for ATP synthesis.  
 
Modeling the HD-Mn striatal cell metabolomics 
 
The striatum is a unique region of the brain, linked to both neurodegeneration in HD and Mn neurotoxicity. The 
application of untargeted metabolomics to elucidate the mechanisms through which control and HD murine 
striatal cells respond to low, moderate non-toxic, and high toxicological Mn levels revealed selective alterations 
in cellular stress responses. Given that the HD genotype disrupts a variety of cellular processes including 
transcriptional regulation, HD striatal cells may have adapted their metabolism to survive under this genotypic 
stressor. Their response to the pathogenic processes of mutant HTT may activate compensatory processes that 
influence Mn toxicity and oxidative stress metabolites (Figure 20). In modeling the observed phenotypes, we 
postulate that the HD genotype produces a state of chronic oxidative stress, depleting cellular GSH reserves. In 
response, HD striatal cells have a deficit in pantothenic acid, hampering efforts to replenish the limited GSH 
reserves. A compensatory process may be induced by HD striatal cells, increased reliance on the pentose shunt 
pathway to regenerate GSH, when cellular Mn burden reaches cytotoxic levels. The exaggerated response to 
Mn is especially noteworthy given the decreased ability of HD striatal cells to accumulate Mn (Williams et al. 
2010, Williams et al. 2010). The decreased Mn uptake by HD striatal cells may also explain the selective 
increase of isobutyrl carnitine levels in control cells at toxic Mn levels.  
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Figure 20 – Metabolic disruption in Huntington’s disease. Summary diagram describing the proposed model 
of HD-Mn interaction based on untargeted metabolomics. Increased metabolite levels indicated by arrows 
(green), decreased metabolite levels by lines (red), and muted increases in metabolites by dashed arrows 
(gray). 
 
 
 
 
Conclusions 
 
In summary, we report the application of untargeted metabolomics to provide insight into the processes 
mediating the complex interactions of genotype and levels of the essential metal, Mn, in the context of HD. This 
unbiased approach revealed disruption in the levels of several diverse physiological and energetic processes by 
Mn and/or HD genotype. Furthermore, the examination of response to low, moderate, and high Mn levels using 
untargeted metabolomics provided a unique perspective on the response of HD striatal cells on a global cellular 
scale. While we identified metabolites with known links to HD pathogenesis such as GSH (Browne et al. 2006), 
the classification of changes in pantothenic acid and the pentose shunt pathway implicate disruption in basal 
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energetic metabolism in HD. In addition, our studies identify alterations in the isobutryryl carnitine, a product 
of fatty acid metabolism. Further examination of the identified cellular processes may provide future 
mechanistic understanding into the loss of striatal neurons in HD and may serve as a framework for future 
therapeutic interventions for this highly debilitating disorder. Our approach can be applied to a variety of other 
poorly understood disease contexts where a particular environmental exposure is linked to disease progression 
or severity. 
 
Materials and Methods 
 
Cell Culture and Sample Preparation 
 
Biological triplicates were prepared for all experiments performed. The clonal striatal cell lines—both mutant 
STHdh[Q111/Q111] and wild-type STHdh[Q7/Q7] were grown at 33°C (Trettel et al. 2000). Culture and 
exposures were performed as previously described.(Williams et al. 2010, Kumar et al. 2013) Subsequently, 
STHdh[Q111/Q111] and wild-type STHdh[Q7/Q7] cells were plated at equal density the 16 hours before 
treatment. Cells were exposed for 3 hours in HBSS (Corning-CellGro) with or without 31µM or 125µM MnCl2 
added. Cells were harvested post-exposure by HPLC-grade methanol (Sigma) extraction and snap frozen in 
liquid nitrogen. Prior to the assay day, samples were thawed and vigorously mixed by a laboratory vortexer and 
centrifuged at 4°C and 14,000×g for 10 min to precipitate proteins and particulates. The supernatants were 
transferred to a fresh tube and vacuum centrifuged until dry. The residuals were stored at -80°C until UPLC-IM-
MSE sample preparation. 
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UPLC-IM-MSE Data Acquisition 
 
The dried metabolite extracts were resuspended in 200µL water with 0.1% formic acid. UPLC-IM-MSE data 
acquisition was performed with a 30-minute gradient. Mobile phase A consisted of H2O with 0.1% formic acid 
and mobile phase B consisted of ACN with 0.1% formic acid. A 1x100 mm 1.7µm particle BEH-T3 C18 column 
(Waters Co) was used for chromatographic separations with a flow rate of 75 µL/min, a column temperature of 
40 °C. An autosampler was used for sample injection and held at 4°C, with a loop size of 5µL. The initial 
solvent composition was 100% A, which was held for 1 min and ramped to 0% A over the next 11 minutes, 
held at 0% A for 2 minutes and returned to 100% A over a 0.1 minute period. The gradient was held at 100% A 
for the next 10.9 minutes for equilibration. Ten column-load injections were performed with 5µL injections of 
the quality control. Quality control injections were then performed after every 10th sample injection to ensure 
instrument stability.  
 
IM-MSE spectra were acquired at a rate of 2 Hz from 50-2000 Da in positive mode for the duration of the 
injection on a Synapt G2 HDMS platform (Waters, Milford, MA). The instrument was calibrated to less than 1 
ppm mass accuracy using sodium formate clusters prior to analysis. A two-point internal standard of leucine 
enkephalin was infused in parallel at a flow rate of 7µL/min and acquired every 10 seconds. The source 
capillary was held at 110°C and 3.0 kV, with a desolvation gas flow of 400 L/hr and a temperature of 150°C. 
The sampling cone was held at a setting of 35.0, with the extraction cone at a setting of 5.0. In the MSE 
configuration, low and high energy spectra are acquired for each scan. High energy data performed a collision 
energy profile from 10-30 eV in the trapping region, providing post-mobility fragmentation. Ion mobility 
separations were performed with a wave velocity of 550m/s, a wave height of 40.0 V, and a nitrogen gas flow 
of 90 mL/min, with the helium cell flow rate at 180mL/min. A leucine encephalin internal calibrant correction 
was performed in real time. 
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Data processing and statistical analysis 
 
Data were converted to mzXML format using the msconvert tool from the ProteoWizard package as previously 
described (Kessner et al. 2008). Peak picking and alignment were performed using XCMS in R (Smith et al. 
2006). The resulting data matrix contained 475 detected features. Features were pre-filtered for reproducibility 
using an ANOVA threshold of p ≤ 0.10, comparing across all experimental conditions and biological replicates. 
Prior to self-organizing map (SOM) analyses, MVSA, and further statistical analyses, analytical triplicates were 
averaged. For GEDI analysis, a grid of 25 x 26 was generated, with 100 first phase training iterations and 160 
second phase. An initial training radius of 10.0 was defined with a learning factor of 0.5, a neighborhood block 
size of 20, and a conscience of 5.0. For the second phase, a neighborhood radius of 1.0, learning factor of 0.05, 
neighborhood block size of 2, and conscience of 2.0 was defined. A random seed of 10 with a Pearson’s 
correlation distance metric and random selection initialization was used. Further statistical analyses were 
performed in SPSS version 22 (SPSS, Inc. Chicago, IL). 
 
Metabolite identification 
 
Metabolite identifications were performed using accurate mass measurements and fragmentation spectra 
extracted from IM-MSE data (Table 6, Figures 21-25). Utilizing drift time correlations, product ions were 
correlated appropriately to precursors for extraction of high energy spectra. Annotated spectra are presented in 
Figures 21-25. Identification confidence levels are in accordance with the Metabolomics Standards Initiative 
proposed minimum reporting standards (Sumner et al. 2007). 
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Figure 21 – Intact (above) and mobility-selected fragmentation spectra for glutathione. 
 
 
Figure 22 – Fragmentation spectra for ribulose 5-phosphate. 
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Figure 23 – Isotopic envelope suggesting ubiquitin identification. 
 
 
Figure 24 – Pantothenic acid fragmentation spectrum. 
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Figure 25 – Mobility-selected high (above) and low (below) energy spectra for isobutyryl carnitine. 
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CHAPTER VII 
 
REGULATION OF NEURONAL MN IN PHYSIOLOGY AND DISEASE: CONCLUSIONS AND 
FUTURE DIRECTIONS 
 
Regulation of Mn content in dopaminergic neurons: evidence of homeostatic developmental regulation 
 
The role of essential metals in development and function of the nervous system have been particularly well 
described for major metals such as iron and zinc. However, the regulation of Mn at the level of neurons is a 
poorly understood process. Given known developmental exposures and the identified role of Mn as a risk factor 
for parkinsonism and Huntington’s disease, we sought to understand how Mn is regulated in the nervous 
system. The limited availability of pharmacological agents capable of manipulating neuronal Mn content has 
impeded the study of this process. To overcome this obstacle, we developed an innovative chemical biology 
approach consisting of a high throughput screen based on the cellular fura-2 Mn extraction assay (CFMEA), an 
assay that can detect modulators of cellular Mn status. Using this approach, we developed a highly diverse 
small molecule toolbox that could increase and decrease Mn levels under toxicologically relevant Mn 
exposures. Furthermore, the vast majority (39/41) small molecules exhibited activity at physiological Mn levels. 
We performed a chemical informatics analysis to identify potential signaling pathways and proteins targeted by 
the small molecule toolbox. This analysis identified major signaling pathways such as MAPK14, TGFBR1, 
SOD1, and HIF1-α as well as enzymes involved in neurotransmission such as ACHE and BCHE. Identification 
of novel pathways and enzymes associated with Mn exposure provides direction for future study into the 
processes underlying Mn biology. 
 
Given that the toolbox was developed in an immortalized murine striatal cell system, we sought to evaluate the 
efficacy of selected small molecules in a human induced pluripotent stem cell (hiPSC) system. Interrogating Mn 
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biology in a hiSPC based system provided multiple advantages, including: (1) translating our findings from 
murine to human system, (2) evaluating changes in Mn content across neurodevelopmental time, and (3) 
revealing differences in activity of particular small molecules based on developmental stage. Our studies 
revealed that neuronal Mn content changes across developmental time. Furthermore, the variety of small 
molecule activity patterns may indicate that the highly complex processes regulating neuronal Mn change 
across developmental time. This work provides the first evidence of cell-level regulation of neuronal Mn 
content across neural differentiation. 
 
In addition to our high throughput screening approach, we sought to investigate how neurons respond to altered 
states of Mn exposure in the context of a genotypic stressor. Using the immortalized murine system, we were 
able to compare striatal neurons expressing mutant and wild-type Huntingtin in the context of physiological and 
toxicological Mn states. Using an untargeted metabolomics approach, we revealed metabolic evidence of a 
genotype-environment interaction between Mn and HD genotype. The physiological processes affected by Mn 
and/or HD genotype regulate cellular energetics, neuronal function, and response to oxidative stress. 
 
Efficacy of the small molecule toolbox: insights into neuronal Mn regulation 
 
The activity of the small molecule toolbox in murine and human systems provides an insight into the processes 
regulating neuronal Mn.  Firstly, this study establishes that mechanisms of neuronal Mn regulation are 
pharmacologically targetable. The vast majority of these small molecules are capable of modulating Mn at both 
physiological and toxicological exposure conditions, suggestive that the targeted regulatory mechanisms that 
function in normal neuronal physiology modulate Mn under high exposure conditions. The exposure paradigm 
utilized in our studies is an important consideration when interpreting their findings. The Mn toolbox small 
molecules were identified in an acute exposure paradigm while epidemiological evidence suggests chronic 
exposures contribute to neurodegenerative diseases. However, there are a number of acute exposure settings, 
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such intravenous delivery of diagnostic imaging contrast agents, that have clinical relevance. It is plausible that 
the mechanisms targeted by the HTS-identified small molecules in an acute exposure function similarly in the 
context of a chronic exposure. In addition, the majority of small molecules were relatively low potency, 
requiring concentrations of 0.1 – 10µM to achieve a detectable effect. This low potency complicates 
interpretation of the functional targets revealed by STITCH since the observed effect on Mn content could be 
caused by off-target interactions. The high concentration required could also reflect a lack of affinity of small 
molecules for their active site, suggestive that a increasing concentration would enhance active site occupancy 
allowing for a rapid shift in Mn content under an acute Mn exposure. It is plausible that low small molecule 
concentrations could show efficacy in a chronic exposure paradigm. An additional factor that may contribute to 
the low potency of the toolbox small molecules is the relative ability of the compounds to cross cell membranes, 
a property critical for accessing intracellular targets. Regardless of the nature of the observed low potency, there 
is tremendous potential for lead optimization and medicinal chemistry to improve the affinity and stability of 
the small molecule Mn toolbox. 
 
Another interesting aspect of the small molecule Mn toolbox is its composition. Despite performing a screen 
across a highly diverse chemical library, there were substantially more Mn level increasing than decreasing 
small molecules. The Mn level increasers could be composed of small molecules that enhance Mn uptake or 
conversely inhibit Mn efflux. Operating under the assumption that the HTS was equally powered to detect Mn 
level increasing and decreasing small molecules, this finding would suggest that the identified small molecules 
disrupt the activity of efflux mechanisms. Alternatively, there may exist a limited set of functional targets for 
which these small molecules act as activators. Notably, 7/8 Mn level decreasers had lower effect size, as defined 
as the fold change in Mn level, at physiological Mn exposures than at toxicological exposures. In contrast, there 
was profound variation in the effect size for Mn level increasing small molecules between physiological and 
toxicological exposures. This variation may reflect diversity of the functional targets for Mn level increasing 
small molecules whereas the Mn level decreasing may act on the same or functionally similar targets. The 
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finding that members of chemical families, such as Cluster 3, exhibit similar effect size at physiological and 
toxicological exposures further supports this observation. 
 
Lastly, we gained insight into the temporal changes in Mn regulation across human dopaminergic neuron 
developmental time using hiPSC technology. As mesencephalic neural progenitors differentiate to post-mitotic 
dopaminergic neurons, there is a significant increase in Mn content under toxicological exposure conditions. In 
addition, all of the tested small molecules identified in the murine-based high throughput screen were effective 
in the human dopaminergic neuron system. This suggests that the Mn regulatory mechanisms targeted by the 
small molecules are highly conserved between mice and humans. Furthermore, two of the small molecules 
exhibited developmental specificity, suggestive that their functional targets change across neural differentiation 
and that the small molecules act through cell-specific mechanisms. This demonstration of cell-specific Mn 
homeostatic mechanisms that are modulated across development supports our hypothesis that Mn is regulated at 
the neuronal level. 
 
Future directions: identification of mechanistic targets of neuronal Mn regulation and in vivo studies 
 
Taken together, our innovative chemical biology approach provides evidence of a highly sophisticated, 
regulatory environment mediating neuronal Mn content. This regulatory system is likely necessary given the 
role of Mn in critical cellular processes, such as mediating oxidative stress, which neurons are acutely sensitive. 
Perturbation of Mn biology, particularly in development, has the ability to limit or hasten the onset of 
neurodegenerative diseases such as parkinsonism and Huntington’s disease. In cases where there is a known 
genetic predisposition or high occupational exposure, there is immense potential in neuroprotective therapeutics 
to limit Mn-induced pathology. The putative targets identified by the high throughput screen and untargeted 
metabolomics studies may represent therapeutic targets for manipulation of neuronal Mn handling. 
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To capitalize on the therapeutic potential of Mn manipulation, future studies are directed along two major aims: 
(1) further characterization of novel Mn regulatory pathways and (2) translation of the small molecule toolbox 
for in vivo applications. The putative identification of Mn regulatory pathways by our studies provides a known 
set of proteins that can be targeted. In order to evaluate each regulatory element individually, we will employ a 
combination of pharmacological and molecular biology techniques. For those small molecules with a known 
mechanism of action, such as kinase inhibitors, we will conduct activity profiling to determine whether on-
target or off-target effects cause the observed effect on Mn content. For those with well-defined targetable site, 
we will then perform competition experiments with the Mn toolbox small molecule alongside other known 
inhibitors and activators for the same target. These studies will be able to determine whether a particular small 
molecule target can be manipulated bidirectionally, both to increase and decrease neuronal Mn content, and 
evaluate dose responsive activity. This pharmacological approach can be conducted in a high throughput 
capacity, allowing rapid refinement of the list of functional targets. We have performed preliminary competition 
studies examining the three small molecules from the GSK Published Kinase Inhibitor Set, which have 
characterized pharmacological profiles (Figure 26). VU0482723 and VU0482794 were designed to target 
epidermal growth factor receptor/human epidermal growth factor receptor 2 (EGFR/HER2) while VU0482585 
was designed to target TGFβ type I receptor kinase (ALK5). The lack of clear additive effects between these 
small molecules and known target-specific drugs in the competition studies suggests that changes in neuronal 
Mn status likely resulted from off-target effects at another kinase. 
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Figure 26 – Competition experiments for GSK Published Kinase Inhibitor Set small molecules. (A) 
Individual activity of EGFR/HER2 primary target small molecules. (B) Competition experiment of 
VU0482723. (C) Individual activity of ALK primary target small molecules. (D) Competition experiment of 
VU0482585.  Identity of small molecule/drug followed by primary target is indicated by (Small Molecule – 
Target). Log(inhibitor) vs. response best fit curves were generated and plotted for each small molecule. n=4 for 
each data point. 
 
Since pharmacological interrogation is limited by the availability of high affinity compounds with established 
specificity, mechanistic targets can also be explored with molecular biology techniques. For example, using 
siRNA or CRISPR/Cas system, these Mn regulatory functional targets can be knocked down or out, allowing 
determination of the specificity of the functional effect. This simple approach has the ability to identify critical 
genes regulating neuronal Mn. 
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While refinement of functional targets will permit assessment of the cellular mechanisms regulating neuronal 
Mn, we have profound interest in whether HTS-identified small molecules will have efficacy in vivo. Prior to in 
vivo work in an animal model, extensive pharmacokinetic studies (brain-to-plasma, clearance, 
metabolism/stability) would first be required. These experiments would determine the route of administration 
(oral, subcutaneous, or intrathecal) and the clearance of the small molecule in other tissue types. These studies 
would be followed by any necessary medicinal chemistry and lead optimization of our toolbox small molecules. 
In addition, adaptation of our in vitro Mn exposure paradigms to in vivo systems and identifying robust social or 
motor behavioral outcomes would be required. These prerequisite studies would permit the examination of 
small molecule efficacy in the developing and adult mouse brain.  
 
A multidisciplinary approach to reveal new therapeutic targets for disease  
 
Aside from the direct conclusions of our work, perhaps one of the most important implications of the overall 
project was its unique approach. By leveraging the advantages of HTS technology, human induced pluripotent 
stem cells, and untargeted metabolomics, we were able to explore poorly understood processes underlying 
regulation of an essential metal from multiple perspectives. Basic science and clinical medicine have made 
fundamental breakthroughs for pathologies where a single target can halt or reverse disease progression (i.e. 
VEGF in age related macular degeneration, HER2 in breast cancer) however this is not the case for the vast 
majority of illnesses. In HD for example, the expanded CAG repeat responsible for the disorder has been known 
for over 20 years, yet a firm understanding of HD pathogenesis remains elusive. Our group’s discovery of 
resistance of Mn accumulation and toxicity in HD presented the opportunity to interrogate a single phenotype 
using a multidisciplinary approach. In a similar fashion, Mn was an established epidemiological risk factor for 
parkinsonism including manganism and PD. Our optimization of CFMEA quantify cellular Mn content 
permitted screening a large chemical library for modulators of neuronal Mn status while naïve to the mechanism 
of action of individual small molecules. Similarly, untargeted metabolomics allowed assessment of the global 
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metabolite changes in response to genotype and Mn burden. Although they each technique provided a different 
perspective, both approaches provided complementary insight into neuronal Mn regulation. Subsequently, 
hiPSC technology allowed the application of the small molecule toolbox to assess Mn regulation in the context 
of human neurodevelopment. The combination of HTS and untargeted metabolomics using hiSPC technology is 
broadly applicable to any pathology with known links to an environmental or iatrogenic agent. The recent 
advent of these technologies made a nearly impossible task, screening thousands of chemicals and metabolite 
identification, an achievable goal. Furthermore, this approach has the potential to accelerate discovery of 
mechanisms underlying cellular physiology and disease pathogenesis.
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